<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T11:00:01Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:5586475" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:5586475</identifier>
        <datestamp>2017-09-11</datestamp>
        <setSpec>jaha</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" article-type="research-article">
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">J Am Heart Assoc</journal-id>
              <journal-id journal-id-type="iso-abbrev">J Am Heart Assoc</journal-id>
              <journal-id journal-id-type="doi">10.1002/(ISSN)2047-9980</journal-id>
              <journal-id journal-id-type="publisher-id">JAH3</journal-id>
              <journal-id journal-id-type="hwp">ahaoa</journal-id>
              <journal-title-group>
                <journal-title>Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease</journal-title>
              </journal-title-group>
              <issn pub-type="epub">2047-9980</issn>
              <publisher>
                <publisher-name>John Wiley and Sons Inc.</publisher-name>
                <publisher-loc>Hoboken</publisher-loc>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC5586475</article-id>
              <article-id pub-id-type="pmcid">PMC5586475</article-id>
              <article-id pub-id-type="pmc-uid">5586475</article-id>
              <article-id pub-id-type="pmid">28775061</article-id>
              <article-id pub-id-type="pmid">28775061</article-id>
              <article-id pub-id-type="doi">10.1161/JAHA.117.006636</article-id>
              <article-id pub-id-type="publisher-id">JAH32453</article-id>
              <article-categories>
                <subj-group subj-group-type="overline">
                  <subject>Original Research</subject>
                </subj-group>
                <subj-group subj-group-type="heading">
                  <subject>Original Research</subject>
                  <subj-group subj-group-type="heading">
                    <subject>Epidemiology</subject>
                  </subj-group>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>Association of High‐Density Lipoprotein‐Cholesterol Versus Apolipoprotein A‐I With Risk of Coronary Heart Disease: The European Prospective Investigation Into Cancer‐Norfolk Prospective Population Study, the Atherosclerosis Risk in Communities Study, and the Women's Health Study</article-title>
                <alt-title alt-title-type="left-running-head">van Capelleveen et al</alt-title>
              </title-group>
              <contrib-group>
                <contrib id="jah32453-cr-0001" contrib-type="author">
                  <name>
                    <surname>van Capelleveen</surname>
                    <given-names>Julian C.</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref ref-type="aff" rid="jah32453-aff-0001">
                    <sup>1</sup>
                  </xref>
                  <xref ref-type="author-notes" rid="jah32453-note-0002">
                    <sup>†</sup>
                  </xref>
                </contrib>
                <contrib id="jah32453-cr-0002" contrib-type="author">
                  <name>
                    <surname>Bochem</surname>
                    <given-names>Andrea E.</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref ref-type="aff" rid="jah32453-aff-0002">
                    <sup>2</sup>
                  </xref>
                  <xref ref-type="aff" rid="jah32453-aff-0007">
                    <sup>7</sup>
                  </xref>
                  <xref ref-type="author-notes" rid="jah32453-note-0002">
                    <sup>†</sup>
                  </xref>
                </contrib>
                <contrib id="jah32453-cr-0003" contrib-type="author">
                  <name>
                    <surname>Boekholdt</surname>
                    <given-names>S. Matthijs</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref ref-type="aff" rid="jah32453-aff-0002">
                    <sup>2</sup>
                  </xref>
                  <xref ref-type="author-notes" rid="jah32453-note-0002">
                    <sup>†</sup>
                  </xref>
                </contrib>
                <contrib id="jah32453-cr-0004" contrib-type="author">
                  <name>
                    <surname>Mora</surname>
                    <given-names>Samia</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref ref-type="aff" rid="jah32453-aff-0005">
                    <sup>5</sup>
                  </xref>
                </contrib>
                <contrib id="jah32453-cr-0005" contrib-type="author">
                  <name>
                    <surname>Hoogeveen</surname>
                    <given-names>Ron C.</given-names>
                  </name>
                  <degrees>PhD</degrees>
                  <xref ref-type="aff" rid="jah32453-aff-0006">
                    <sup>6</sup>
                  </xref>
                </contrib>
                <contrib id="jah32453-cr-0006" contrib-type="author">
                  <name>
                    <surname>Ballantyne</surname>
                    <given-names>Christie M.</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref ref-type="aff" rid="jah32453-aff-0006">
                    <sup>6</sup>
                  </xref>
                </contrib>
                <contrib id="jah32453-cr-0007" contrib-type="author">
                  <name>
                    <surname>Ridker</surname>
                    <given-names>Paul M</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref ref-type="aff" rid="jah32453-aff-0005">
                    <sup>5</sup>
                  </xref>
                </contrib>
                <contrib id="jah32453-cr-0008" contrib-type="author">
                  <name>
                    <surname>Sun</surname>
                    <given-names>Wensheng</given-names>
                  </name>
                  <degrees>MPH</degrees>
                  <xref ref-type="aff" rid="jah32453-aff-0006">
                    <sup>6</sup>
                  </xref>
                </contrib>
                <contrib id="jah32453-cr-0009" contrib-type="author">
                  <name>
                    <surname>Barter</surname>
                    <given-names>Philip J.</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref ref-type="aff" rid="jah32453-aff-0004">
                    <sup>4</sup>
                  </xref>
                </contrib>
                <contrib id="jah32453-cr-0010" contrib-type="author">
                  <name>
                    <surname>Tall</surname>
                    <given-names>Alan R.</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref ref-type="aff" rid="jah32453-aff-0007">
                    <sup>7</sup>
                  </xref>
                </contrib>
                <contrib id="jah32453-cr-0011" contrib-type="author">
                  <name>
                    <surname>Zwinderman</surname>
                    <given-names>Aeilko H.</given-names>
                  </name>
                  <degrees>PhD</degrees>
                  <xref ref-type="aff" rid="jah32453-aff-0003">
                    <sup>3</sup>
                  </xref>
                </contrib>
                <contrib id="jah32453-cr-0012" contrib-type="author">
                  <name>
                    <surname>Kastelein</surname>
                    <given-names>John J. P.</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref ref-type="aff" rid="jah32453-aff-0001">
                    <sup>1</sup>
                  </xref>
                </contrib>
                <contrib id="jah32453-cr-0013" contrib-type="author">
                  <name>
                    <surname>Wareham</surname>
                    <given-names>Nick J.</given-names>
                  </name>
                  <degrees>MBBS</degrees>
                  <xref ref-type="aff" rid="jah32453-aff-0008">
                    <sup>8</sup>
                  </xref>
                </contrib>
                <contrib id="jah32453-cr-0014" contrib-type="author">
                  <name>
                    <surname>Khaw</surname>
                    <given-names>Kay‐Tee</given-names>
                  </name>
                  <degrees>MBBChir</degrees>
                  <xref ref-type="aff" rid="jah32453-aff-0009">
                    <sup>9</sup>
                  </xref>
                </contrib>
                <contrib id="jah32453-cr-0015" contrib-type="author" corresp="yes">
                  <name>
                    <surname>Hovingh</surname>
                    <given-names>G. Kees</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <address>
                    <email>g.k.hovingh@amc.uva.nl</email>
                  </address>
                  <xref ref-type="aff" rid="jah32453-aff-0001">
                    <sup>1</sup>
                  </xref>
                </contrib>
              </contrib-group>
              <aff id="jah32453-aff-0001">
                <label>
                  <sup>1</sup>
                </label>
                <named-content content-type="organisation-division">Department of Vascular Medicine</named-content>
                <institution>Academic Medical Center</institution>
                <named-content content-type="city">Amsterdam</named-content>
                <country country="NL">The Netherlands</country>
              </aff>
              <aff id="jah32453-aff-0002">
                <label>
                  <sup>2</sup>
                </label>
                <named-content content-type="organisation-division">Department of Cardiology</named-content>
                <institution>Academic Medical Center</institution>
                <named-content content-type="city">Amsterdam</named-content>
                <country country="NL">The Netherlands</country>
              </aff>
              <aff id="jah32453-aff-0003">
                <label>
                  <sup>3</sup>
                </label>
                <named-content content-type="organisation-division">Department of Biostatistics</named-content>
                <institution>Academic Medical Center</institution>
                <named-content content-type="city">Amsterdam</named-content>
                <country country="NL">The Netherlands</country>
              </aff>
              <aff id="jah32453-aff-0004">
                <label>
                  <sup>4</sup>
                </label>
                <named-content content-type="organisation-division">School of Medical Sciences</named-content>
                <institution>University of New South Wales</institution>
                <named-content content-type="city">Sydney</named-content>
                <country country="AU">Australia</country>
              </aff>
              <aff id="jah32453-aff-0005">
                <label>
                  <sup>5</sup>
                </label>
                <named-content content-type="organisation-division">Brigham and Women's Hospital</named-content>
                <institution>Harvard Medical School</institution>
                <named-content content-type="city">Boston</named-content>
                <named-content content-type="country-part">MA</named-content>
              </aff>
              <aff id="jah32453-aff-0006">
                <label>
                  <sup>6</sup>
                </label>
                <named-content content-type="organisation-division">Department of Medicine</named-content>
                <institution>Baylor College of Medicine</institution>
                <named-content content-type="city">Houston</named-content>
                <named-content content-type="country-part">TX</named-content>
              </aff>
              <aff id="jah32453-aff-0007">
                <label>
                  <sup>7</sup>
                </label>
                <named-content content-type="organisation-division">Department of Medicine</named-content>
                <institution>Columbia University</institution>
                <named-content content-type="city">New York</named-content>
                <named-content content-type="country-part">NY</named-content>
              </aff>
              <aff id="jah32453-aff-0008">
                <label>
                  <sup>8</sup>
                </label>
                <institution>Medical Research Council Epidemiology Unit</institution>
                <named-content content-type="city">Cambridge</named-content>
                <country country="GB">United Kingdom</country>
              </aff>
              <aff id="jah32453-aff-0009">
                <label>
                  <sup>9</sup>
                </label>
                <named-content content-type="organisation-division">Department of Public Health and Primary Care</named-content>
                <institution>University of Cambridge</institution>
                <country country="GB">United Kingdom</country>
              </aff>
              <author-notes>
                <corresp id="correspondenceTo"><label>*</label><bold>Correspondence to:</bold> G. Kees Hovingh, MD, Department of Vascular Medicine, Academic Medical Center, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands. E‐mail: <email>g.k.hovingh@amc.uva.nl</email></corresp>
                <fn fn-type="equal" id="jah32453-note-0002">
                  <label>†</label>
                  <p>Dr van Capelleveen and Dr Bochem contributed equally to this work.</p>
                </fn>
              </author-notes>
              <pub-date pub-type="epub">
                <day>03</day>
                <month>8</month>
                <year>2017</year>
              </pub-date>
              <pub-date pub-type="collection">
                <month>8</month>
                <year>2017</year>
              </pub-date>
              <volume>6</volume>
              <issue>8</issue>
              <issue-id pub-id-type="doi">10.1002/jah3.2017.6.issue-8</issue-id>
              <elocation-id>e006636</elocation-id>
              <history>
                <date date-type="received">
                  <day>16</day>
                  <month>5</month>
                  <year>2017</year>
                </date>
                <date date-type="accepted">
                  <day>28</day>
                  <month>6</month>
                  <year>2017</year>
                </date>
              </history>
              <permissions>
                <!--<copyright-statement content-type="issue-copyright"> Copyright &#x000a9; 2017 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley Blackwell <copyright-statement>-->
                <copyright-statement content-type="article-copyright">© 2017 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley.</copyright-statement>
                <license license-type="creativeCommonsBy-nc-nd">
                  <license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/">Creative Commons Attribution‐NonCommercial‐NoDerivs</ext-link> License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.</license-p>
                </license>
              </permissions>
              <self-uri content-type="pdf" xlink:type="simple" xlink:href="file:JAH3-6-e006636.pdf"/>
              <abstract id="jah32453-abs-0001">
                <sec id="jah32453-sec-0001">
                  <title>Background</title>
                  <p>The contribution of apolipoprotein A‐I (apoA‐I) to coronary heart disease (<styled-content style="fixed-case">CHD</styled-content>) risk stratification over and above high‐density lipoprotein cholesterol (<styled-content style="fixed-case">HDL</styled-content>‐C) is unclear. We studied the associations between plasma levels of <styled-content style="fixed-case">HDL</styled-content>‐C and apoA‐I, either alone or combined, with risk of <styled-content style="fixed-case">CHD</styled-content> events and cardiovascular risk factors among apparently healthy men and women.</p>
                </sec>
                <sec id="jah32453-sec-0002">
                  <title>Methods and Results</title>
                  <p><styled-content style="fixed-case">HDL</styled-content>‐C and apoA‐I levels were measured among 17 661 participants of the <styled-content style="fixed-case">EPIC</styled-content> (European Prospective Investigation into Cancer)‐Norfolk prospective population study. Hazard ratios for <styled-content style="fixed-case">CHD</styled-content> events and distributions of risk factors were calculated by quartiles of <styled-content style="fixed-case">HDL</styled-content>‐C and apoA‐I. Results were validated using data from the <styled-content style="fixed-case">ARIC</styled-content> (Atherosclerosis Risk in Communities) and <styled-content style="fixed-case">WHS</styled-content> (Women's Health Study) cohorts, comprising 15 494 and 27 552 individuals, respectively. In <styled-content style="fixed-case">EPIC</styled-content>‐Norfolk, both <styled-content style="fixed-case">HDL</styled-content>‐C and apoA‐I quartiles were strongly and inversely associated with <styled-content style="fixed-case">CHD</styled-content> risk. Within <styled-content style="fixed-case">HDL</styled-content>‐C quartiles, higher apoA‐I levels were not associated with lower <styled-content style="fixed-case">CHD</styled-content> risk; in fact, <styled-content style="fixed-case">CHD</styled-content> risk was higher within some <styled-content style="fixed-case">HDL</styled-content>‐C quartiles. ApoA‐I levels were associated with higher levels of <styled-content style="fixed-case">CHD</styled-content> risk factors: higher body mass index, HbA1c, non‐<styled-content style="fixed-case">HDL</styled-content>‐C, triglycerides, apolipoprotein B, systolic blood pressure, and C‐reactive protein, within fixed <styled-content style="fixed-case">HDL</styled-content>‐C quartiles. In contrast, <styled-content style="fixed-case">HDL</styled-content>‐C levels were consistently inversely associated with overall <styled-content style="fixed-case">CHD</styled-content> risk and <styled-content style="fixed-case">CHD</styled-content> risk factors within apoA‐I quartiles (<italic>P</italic>&lt;0.001). These findings were validated in the <styled-content style="fixed-case">ARIC</styled-content> and <styled-content style="fixed-case">WHS</styled-content> cohorts.</p>
                </sec>
                <sec id="jah32453-sec-0003">
                  <title>Conclusions</title>
                  <p>Our findings demonstrate that apoA‐I levels do not offer predictive information over and above <styled-content style="fixed-case">HDL</styled-content>‐C. In fact, within some <styled-content style="fixed-case">HDL</styled-content>‐C quartiles, higher apoA‐I levels were associated with higher risk of <styled-content style="fixed-case">CHD</styled-content> events, possibly because of the unexpected higher prevalence of cardiovascular risk factors in association with higher apoA‐I levels.</p>
                </sec>
                <sec id="jah32453-sec-0004">
                  <title>Clinical Trial Registration</title>
                  <p><styled-content style="fixed-case">URL</styled-content>: <ext-link ext-link-type="uri" xlink:href="https://www.clinicaltrials.gov">https://www.clinicaltrials.gov</ext-link>. Unique identifier: <styled-content style="fixed-case">NCT</styled-content>00000479.</p>
                </sec>
              </abstract>
              <kwd-group kwd-group-type="author-generated">
                <kwd id="jah32453-kwd-0001">apolipoprotein A‐I</kwd>
                <kwd id="jah32453-kwd-0002">cardiovascular disease</kwd>
                <kwd id="jah32453-kwd-0003">coronary heart disease</kwd>
                <kwd id="jah32453-kwd-0004">high‐density lipoprotein cholesterol</kwd>
              </kwd-group>
              <kwd-group kwd-group-type="subject-categories">
                <title>Subject Categories</title>
                <kwd>Cardiovascular Disease</kwd>
                <kwd>Coronary Artery Disease</kwd>
              </kwd-group>
              <funding-group>
                <award-group>
                  <funding-source>Dutch Heart Foundation</funding-source>
                </award-group>
                <award-group>
                  <funding-source>Vidi</funding-source>
                </award-group>
                <award-group>
                  <funding-source>Netherlands Organisation for Scientific Research</funding-source>
                </award-group>
                <award-group>
                  <funding-source>European Union</funding-source>
                  <award-id>FP7‐603091‐2</award-id>
                </award-group>
                <award-group>
                  <funding-source>Medical Research Council</funding-source>
                  <award-id>MRC G0701863</award-id>
                </award-group>
                <award-group>
                  <funding-source>Molino Family Trust</funding-source>
                  <award-id>HL117861</award-id>
                  <award-id>HL117861‐S1</award-id>
                  <award-id>S2</award-id>
                </award-group>
                <award-group>
                  <funding-source>National Heart, Lung, and Blood Institute</funding-source>
                  <award-id>HL043851</award-id>
                  <award-id>HL 080467</award-id>
                  <award-id>HL 099355</award-id>
                  <award-id>CA 047988</award-id>
                  <award-id>I&lt;1 CA 182913</award-id>
                </award-group>
                <award-group>
                  <funding-source>National Cancer Institute</funding-source>
                </award-group>
                <award-group>
                  <funding-source>National Institutes of Health</funding-source>
                </award-group>
              </funding-group>
              <counts>
                <fig-count count="2"/>
                <table-count count="6"/>
                <page-count count="12"/>
                <word-count count="9009"/>
              </counts>
              <custom-meta-group>
                <custom-meta>
                  <meta-name>source-schema-version-number</meta-name>
                  <meta-value>2.0</meta-value>
                </custom-meta>
                <custom-meta>
                  <meta-name>component-id</meta-name>
                  <meta-value>jah32453</meta-value>
                </custom-meta>
                <custom-meta>
                  <meta-name>cover-date</meta-name>
                  <meta-value>August 2017</meta-value>
                </custom-meta>
                <custom-meta>
                  <meta-name>details-of-publishers-convertor</meta-name>
                  <meta-value>Converter:WILEY_ML3GV2_TO_NLMPMC version:5.1.7 mode:remove_FC converted:24.08.2017</meta-value>
                </custom-meta>
              </custom-meta-group>
            </article-meta>
            <notes>
              <p content-type="self-citation">
                <mixed-citation publication-type="journal" id="jah32453-cit-1001">(<source>J Am Heart Assoc</source>. <year>2017</year>;<volume>6</volume>:<elocation-id>e006636</elocation-id> DOI: <ext-link ext-link-type="doi" xlink:href="10.1161/JAHA.117.006636">10.1161/JAHA.117.006636</ext-link>.)<pub-id pub-id-type="pmid">28775061</pub-id></mixed-citation>
              </p>
            </notes>
          </front>
          <body>
            <p>
              <boxed-text position="anchor" content-type="box" id="jah32453-blkfxd-0001" orientation="portrait">
                <sec id="jah32453-sec-0006">
                  <title>Clinical Perspective</title>
                  <sec id="jah32453-sec-0007">
                    <title>What Is New?</title>
                    <p>
                      <list list-type="bullet" id="jah32453-list-0001">
                        <list-item>
                          <p>In 3 large prospective cohort studies, we found that apolipoprotein A‐I was unexpectedly associated with increased coronary artery disease risk factors within fixed high‐density lipoprotein cholesterol quartiles, and for some quartiles this resulted in increased coronary artery disease risk.</p>
                        </list-item>
                      </list>
                    </p>
                  </sec>
                  <sec id="jah32453-sec-0008">
                    <title>What Are the Clinical Implications?</title>
                    <p>
                      <list list-type="bullet" id="jah32453-list-0002">
                        <list-item>
                          <p>Our results indicate that apolipoprotein does not offer predictive information over and above high‐density lipoprotein cholesterol levels.</p>
                        </list-item>
                      </list>
                    </p>
                  </sec>
                </sec>
              </boxed-text>
            </p>
            <sec id="jah32453-sec-0009">
              <title>Introduction</title>
              <p>Prospective epidemiological studies have consistently shown that plasma levels of high‐density lipoprotein cholesterol (HDL‐C) are inversely associated with coronary heart disease (CHD) risk. However, the biological foundation of this association is controversial. Mendelian randomization studies have shown us that single nucleotide polymorphisms in loci only affecting plasma HDL‐C levels do not associate with CHD risk.<xref rid="jah32453-bib-0001" ref-type="ref">1</xref> The inverse association between HDL‐C and CHD risk has drawn attention to HDL‐C as a pharmacological target to reduce CHD risk. In spite of this, there is currently no evidence in human studies that increasing HDL‐C leads to CHD event reduction.<xref rid="jah32453-bib-0002" ref-type="ref">2</xref>, <xref rid="jah32453-bib-0003" ref-type="ref">3</xref>, <xref rid="jah32453-bib-0004" ref-type="ref">4</xref> Combined, these findings give rise to the notion that HDL‐C itself might not play a causative role in the protection against atherogenesis and have resulted in a search for parameters that reflect the physical structure or function of HDL as a more relevant predictor of CHD risk. Apolipoprotein A‐I (apoA‐I), the major constituent of HDL particles, might be such a parameter. Similar associations with CHD risk have been reported for apoA‐I as for HDL‐C,<xref rid="jah32453-bib-0005" ref-type="ref">5</xref> and antioxidant, anti‐inflammatory, antithrombotic, and nitric oxide–promoting properties have been ascribed to apoA‐I.<xref rid="jah32453-bib-0006" ref-type="ref">6</xref>, <xref rid="jah32453-bib-0007" ref-type="ref">7</xref> These findings have driven the development of therapeutic strategies that infuse apoA‐I or upregulate apoA‐I in the liver that are currently under investigation<xref rid="jah32453-bib-0008" ref-type="ref">8</xref> with varying clinical success.<xref rid="jah32453-bib-0009" ref-type="ref">9</xref>, <xref rid="jah32453-bib-0010" ref-type="ref">10</xref>, <xref rid="jah32453-bib-0011" ref-type="ref">11</xref> Whether apoA‐I is a more relevant therapeutic target over HDL‐C is heavily debated, however.</p>
              <p>Prospective studies comparing the associations of apoA‐I and HDL‐C with risk of future CHD events have shown conflicting results.<xref rid="jah32453-bib-0012" ref-type="ref">12</xref>, <xref rid="jah32453-bib-0013" ref-type="ref">13</xref> A possible explanation lies in the intricate relationship between HDL‐C and apoA‐I levels that is hard to dissect using conventional regression models. Here, we use a new approach by assessing CHD risk based on HDL‐C and apoA‐I quartiles in a 4×4 fashion. The objective of this study was to assess the association of apoA‐I levels with CHD risk and CHD risk factors within fixed HDL‐C quartiles, and vice versa, which requires a large study sample. We pursued this objective in the large European Prospective Investigation into Cancer (EPIC) Norfolk cohort, a prospective population study based in the United Kingdom. Results were validated in the ARIC (Atherosclerosis Risk in Communities) cohort and the WHS (Women's Health Study).</p>
            </sec>
            <sec id="jah32453-sec-0010">
              <title>Methods</title>
              <sec id="jah32453-sec-0011">
                <title>Study Design and Biochemical Analyses</title>
                <sec id="jah32453-sec-0012">
                  <title>The EPIC‐Norfolk study</title>
                  <p>The EPIC‐Norfolk study is a prospective population study of 25 639 male and female residents of Norfolk, United Kingdom, aged between 39 and 79 years. The recruitment process, study design, and population characteristics have been published previously.<xref rid="jah32453-bib-0014" ref-type="ref">14</xref> The study was approved by the Norfolk Local Research Ethics Committee and complies with the declaration of Helsinki. All participants gave written informed consent.</p>
                  <p>All individuals have been flagged for mortality at the UK Office of National Statistics, with vital status ascertained for the entire cohort. Death certificates were coded by trained nosologists according to the <italic>International Classification of Diseases</italic> 10th revision. In addition, hospitalized participants were identified by using their unique National Health Service number through data linkage with the East Norfolk Health Authority (ENCORE) database, which identifies all hospital contacts throughout England and Wales for residents of Norfolk. Participants were identified as having developed CHD during follow‐up if they had a hospital admission and/or died with CHD as the underlying cause during follow‐up. CHD was defined as <italic>International Classification of Diseases</italic> 10th revision codes I20 to I25 (which includes myocardial infarction, angina, and other ischemic heart disease). We report results with follow‐up to March 31, 2008, after a mean of 12.7±2.3 years. Previous validation studies in this cohort indicate a high specificity of case ascertainment.<xref rid="jah32453-bib-0015" ref-type="ref">15</xref>
</p>
                  <p>Blood samples were drawn at the baseline visit in either fasting or nonfasting state. Samples were processed for assay at the Department of Clinical Biochemistry, University of Cambridge, or stored at −80°C. In the entire population study, serum lipids were analyzed for total cholesterol, HDL‐C, and triglyceride on a RA‐1000 analyzer (Bayer Diagnostics, Basingstoke, UK). HDL cholesterol levels were measured after precipitation of non‐HDL particles with N,N‐bis (4‐sulfhobutyl)‐ m‐Toluidine‐disodium (DSBmT) and peroxidase. Low‐density lipoprotein cholesterol levels were calculated with the Friedewald formula.<xref rid="jah32453-bib-0016" ref-type="ref">16</xref> Serum apoA‐I and apolipoprotein B (apoB) levels were measured using rate immunonephelometry (Behring Nephelometer BNII, Marburg, Germany) with calibration traceable to the International Federation of Clinical Chemistry primary standards.<xref rid="jah32453-bib-0017" ref-type="ref">17</xref> Researchers and laboratory personnel had no access to identifiable information and could identify samples by number only.</p>
                </sec>
                <sec id="jah32453-sec-0013">
                  <title>The ARIC Study</title>
                  <p>The ARIC Study is a population‐based prospective cohort study of cardiovascular disease sponsored by the National Heart, Lung, and Blood Institute. ARIC originally included 15 792 individuals aged 45 to 64 years at baseline (1987–1989), chosen by probability sampling from 4 US communities.<xref rid="jah32453-bib-0018" ref-type="ref">18</xref> Cohort members completed 4 clinic examinations each spread over about 3 years, conducted ≈3 years apart between 1987 and 1998. The data used in this study are from the first visit in 1987–1989. A detailed study protocol is available on the ARIC study website (<ext-link ext-link-type="uri" xlink:href="https://www2.cscc.unc.edu/aric/">https://www2.cscc.unc.edu/aric/</ext-link>).</p>
                  <p>ARIC investigators conduct continuous, comprehensive surveillance for all cardiovascular disease–related hospitalizations and deaths in the 4 communities. CHD was adjudicated on the basis of published criteria.<xref rid="jah32453-bib-0019" ref-type="ref">19</xref> CHD was defined as a definite or probable myocardial infarction, definite coronary death, or coronary revascularization procedure. Those with prevalent CHD were excluded for incident CHD analysis. Follow‐up time ended when the participant had a CHD event, died, was lost to follow‐up, or survived until December 30, 2009 with a mean follow‐up time of 20±3.6 years. Serum lipids and apoA‐I levels were measured as previously reported.<xref rid="jah32453-bib-0020" ref-type="ref">20</xref>
</p>
                </sec>
                <sec id="jah32453-sec-0014">
                  <title>The Women's Health Study</title>
                  <p>The WHS (NCT00000479) is a completed randomized, double‐blinded, placebo‐controlled trial of low‐dose aspirin and vitamin E in the primary prevention of cardiovascular disease and cancer in women.<xref rid="jah32453-bib-0021" ref-type="ref">21</xref>, <xref rid="jah32453-bib-0022" ref-type="ref">22</xref> Randomized treatment ended in March 2004, and participants were invited to participate in ongoing observational follow‐up. Participants were apparently healthy female healthcare professionals, ages 45 years or older, who were free of self‐reported cardiovascular disease and cancer at study entry (1992–1996). At the time of enrollment, women gave written informed consent and completed questionnaires on demographics, anthropometrics, medical history, and lifestyle factors. They were also asked to provide a baseline blood sample; 28 345 women did so, and of these, a total of 27 827 had baseline lipid measurements. We excluded women with missing values for any of the lipid or apolipoprotein measurements (N=275), resulting in 27 552 women for this analysis. The study was approved by the institutional review board of the Brigham and Women's Hospital (Boston, MA).</p>
                  <p>The end point of incident CHD was defined as nonfatal myocardial infarction, percutaneous coronary intervention, coronary artery bypass grafting, or coronary death. Information on the occurrence of these end points was ascertained via annual follow‐up questionnaires, letters, and telephone calls. Following written informed consent, medical records were obtained and reviewed by a blinded Endpoints Committee for the adjudication of all reported end points based on predefined criteria as previously described.<xref rid="jah32453-bib-0021" ref-type="ref">21</xref>, <xref rid="jah32453-bib-0022" ref-type="ref">22</xref> We report results with follow‐up through 2012, after a mean of 15.8±3.5 years.</p>
                  <p>HDL‐C was measured with a direct homogeneous polyethylene‐glycol assay, and apoA‐I with an immunoturbidometric assay (DiaSorin, Stillwater, MN). Coefficients of variation for HDL‐C and apoA‐I were &lt;3%.</p>
                </sec>
              </sec>
              <sec id="jah32453-sec-0015">
                <title>Statistical Analysis</title>
                <p>We evaluated the distribution of cardiovascular risk factors across quartiles of HDL‐C and apoA‐I. Metabolic syndrome was defined as previously described.<xref rid="jah32453-bib-0023" ref-type="ref">23</xref> CRP (C‐reactive protein) and triglycerides plasma levels showed a skewed distribution and were log‐transformed before analysis. <italic>P</italic> values for trend across quartiles (and tertiles for WHS) of HDL‐C and apoA‐I were assessed in an unadjusted model using the Jonckheere‐Terpstra test. Cox proportional hazards models were used to calculate hazard ratios and corresponding 95% CI for CHD risk by quartiles of HDL‐C and apoA‐I, using the lowest quartile as a reference, and event‐free survival per quartile was depicted in Kaplan–Meier curves. Unadjusted regression models were used (model 1), as well as regression models adjusting for sex, age, smoking, body mass index, systolic blood pressure, diabetes mellitus, apoB, log‐transformed CRP (model 2), and log‐transformed triglycerides (model 3). In addition, we calculated unadjusted hazard ratios and corresponding 95% CIs for combined quartiles of HDL‐C and apoA‐I. Linear regression analysis was used to assess correlations between HDL‐C and apoA‐I per HDL‐C or apoA‐I quartile. Analyses were undertaken using SPSS (version 18.0).</p>
              </sec>
            </sec>
            <sec id="jah32453-sec-0016">
              <title>Results</title>
              <sec id="jah32453-sec-0017">
                <title>EPIC‐Norfolk</title>
                <p>A complete data set was available for a total number of 17 661 individuals in the EPIC‐Norfolk cohort. This subset did not differ in any of the relevant baseline characteristics from the subset for whom data were missing. A total of 2226 (12.6%) participants experienced a CHD event during follow‐up. Baseline characteristics by quartiles of HDL‐C and apoA‐I are shown in Tables <xref rid="jah32453-tbl-0001" ref-type="table-wrap">1</xref> and <xref rid="jah32453-tbl-0002" ref-type="table-wrap">2</xref>, respectively.</p>
                <table-wrap id="jah32453-tbl-0001" xml:lang="en" orientation="portrait" position="float">
                  <label>Table 1</label>
                  <caption>
                    <p>Baseline Characteristics by HDL Cholesterol Quartiles in the EPIC‐Norfolk Study</p>
                  </caption>
                  <table frame="hsides" rules="groups">
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <thead valign="top">
                      <tr style="border-bottom:solid 1px #000000">
                        <th align="left" rowspan="2" valign="top" colspan="1"/>
                        <th align="left" colspan="4" style="border-bottom:solid 1px #000000" valign="top" rowspan="1">HDL Cholesterol Quartiles</th>
                        <th align="left" rowspan="2" valign="top" colspan="1"><italic>P</italic> Value</th>
                      </tr>
                      <tr style="border-bottom:solid 1px #000000">
                        <th align="left" valign="top" rowspan="1" colspan="1">1</th>
                        <th align="left" valign="top" rowspan="1" colspan="1">2</th>
                        <th align="left" valign="top" rowspan="1" colspan="1">3</th>
                        <th align="left" valign="top" rowspan="1" colspan="1">4</th>
                      </tr>
                    </thead>
                    <tbody>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">N</td>
                        <td align="left" rowspan="1" colspan="1">5031</td>
                        <td align="left" rowspan="1" colspan="1">3595</td>
                        <td align="left" rowspan="1" colspan="1">4444</td>
                        <td align="left" rowspan="1" colspan="1">4591</td>
                        <td align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">HDL cholesterol, mmol/L</td>
                        <td align="left" rowspan="1" colspan="1">1.0±0.1</td>
                        <td align="left" rowspan="1" colspan="1">1.3±0.1</td>
                        <td align="left" rowspan="1" colspan="1">1.5±0.1</td>
                        <td align="left" rowspan="1" colspan="1">2.0±0.3</td>
                        <td align="left" rowspan="1" colspan="1">&lt;0.001</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Age, y</td>
                        <td align="left" rowspan="1" colspan="1">59.6±9.1</td>
                        <td align="left" rowspan="1" colspan="1">59.3±9.1</td>
                        <td align="left" rowspan="1" colspan="1">59±9.1</td>
                        <td align="left" rowspan="1" colspan="1">58.8±9.3</td>
                        <td align="left" rowspan="1" colspan="1">&lt;0.001</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Male sex</td>
                        <td align="left" rowspan="1" colspan="1">71% (3572)</td>
                        <td align="left" rowspan="1" colspan="1">51% (1834)</td>
                        <td align="left" rowspan="1" colspan="1">35% (1555)</td>
                        <td align="left" rowspan="1" colspan="1">19% (872)</td>
                        <td align="left" rowspan="1" colspan="1">&lt;0.001</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Body mass index, kg/m<sup>2</sup>
</td>
                        <td align="left" rowspan="1" colspan="1">27.3±3.7</td>
                        <td align="left" rowspan="1" colspan="1">26.5±3.67</td>
                        <td align="left" rowspan="1" colspan="1">25.9±3.8</td>
                        <td align="left" rowspan="1" colspan="1">24.9±3.5</td>
                        <td align="left" rowspan="1" colspan="1">&lt;0.001</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Diabetes mellitus, % (n)</td>
                        <td align="left" rowspan="1" colspan="1">3.0 (149)</td>
                        <td align="left" rowspan="1" colspan="1">2.1 (75)</td>
                        <td align="left" rowspan="1" colspan="1">1.8 (79)</td>
                        <td align="left" rowspan="1" colspan="1">1.2 (55)</td>
                        <td align="left" rowspan="1" colspan="1">&lt;0.001</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">HbA1c, %</td>
                        <td align="left" rowspan="1" colspan="1">5.4±1.0</td>
                        <td align="left" rowspan="1" colspan="1">5.3±0.8</td>
                        <td align="left" rowspan="1" colspan="1">5.3±0.8</td>
                        <td align="left" rowspan="1" colspan="1">5.2±0.7</td>
                        <td align="left" rowspan="1" colspan="1">&lt;0.001</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Systolic blood pressure, mm Hg</td>
                        <td align="left" rowspan="1" colspan="1">136±18</td>
                        <td align="left" rowspan="1" colspan="1">136±18</td>
                        <td align="left" rowspan="1" colspan="1">134±18</td>
                        <td align="left" rowspan="1" colspan="1">133±19</td>
                        <td align="left" rowspan="1" colspan="1">&lt;0.001</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Diastolic blood pressure, mm Hg</td>
                        <td align="left" rowspan="1" colspan="1">83±11</td>
                        <td align="left" rowspan="1" colspan="1">83±11</td>
                        <td align="left" rowspan="1" colspan="1">82±11</td>
                        <td align="left" rowspan="1" colspan="1">81±11</td>
                        <td align="left" rowspan="1" colspan="1">&lt;0.001</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Total cholesterol, mmol/L</td>
                        <td align="left" rowspan="1" colspan="1">6.0±1.2</td>
                        <td align="left" rowspan="1" colspan="1">6.2±1.1</td>
                        <td align="left" rowspan="1" colspan="1">6.2±1.1</td>
                        <td align="left" rowspan="1" colspan="1">6.3±1.1</td>
                        <td align="left" rowspan="1" colspan="1">&lt;0.001</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">LDL cholesterol, mmol/L</td>
                        <td align="left" rowspan="1" colspan="1">4.0±1.0</td>
                        <td align="left" rowspan="1" colspan="1">4.1±1.0</td>
                        <td align="left" rowspan="1" colspan="1">4.0±1.0</td>
                        <td align="left" rowspan="1" colspan="1">3.7±1.0</td>
                        <td align="left" rowspan="1" colspan="1">&lt;0.001</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Non‐HDL cholesterol, mmol/L</td>
                        <td align="left" rowspan="1" colspan="1">5.0±1.2</td>
                        <td align="left" rowspan="1" colspan="1">4.9±1.1</td>
                        <td align="left" rowspan="1" colspan="1">4.7±1.1</td>
                        <td align="left" rowspan="1" colspan="1">4.2±1.1</td>
                        <td align="left" rowspan="1" colspan="1">&lt;0.001</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Triglycerides, mmol/L</td>
                        <td align="left" rowspan="1" colspan="1">2.0 (1.5–2.7)</td>
                        <td align="left" rowspan="1" colspan="1">1.7 (1.2–2.2)</td>
                        <td align="left" rowspan="1" colspan="1">1.4 (1.0–1.9)</td>
                        <td align="left" rowspan="1" colspan="1">1.1 (0.8–1.5)</td>
                        <td align="left" rowspan="1" colspan="1">&lt;0.001</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Apolipoprotein A‐I, mg/dL</td>
                        <td align="left" rowspan="1" colspan="1">129±22</td>
                        <td align="left" rowspan="1" colspan="1">148±23</td>
                        <td align="left" rowspan="1" colspan="1">161±26</td>
                        <td align="left" rowspan="1" colspan="1">184±30</td>
                        <td align="left" rowspan="1" colspan="1">&lt;0.001</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Apolipoprotein B, mg/dL</td>
                        <td align="left" rowspan="1" colspan="1">100±25</td>
                        <td align="left" rowspan="1" colspan="1">99±24</td>
                        <td align="left" rowspan="1" colspan="1">96±24</td>
                        <td align="left" rowspan="1" colspan="1">92±23</td>
                        <td align="left" rowspan="1" colspan="1">&lt;0.001</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">C‐reactive protein, mg/L</td>
                        <td align="left" rowspan="1" colspan="1">2.0 (0.9–4.3)</td>
                        <td align="left" rowspan="1" colspan="1">1.6 (0.8–3.6)</td>
                        <td align="left" rowspan="1" colspan="1">1.6 (0.8–3.5)</td>
                        <td align="left" rowspan="1" colspan="1">1.3 (0.6–2.7)</td>
                        <td align="left" rowspan="1" colspan="1">&lt;0.001</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Metabolic syndrome</td>
                        <td align="left" rowspan="1" colspan="1">83% (4176)</td>
                        <td align="left" rowspan="1" colspan="1">70% (2517)</td>
                        <td align="left" rowspan="1" colspan="1">63% (2800)</td>
                        <td align="left" rowspan="1" colspan="1">56% (2571)</td>
                        <td align="left" rowspan="1" colspan="1">&lt;0.001</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Alcohol intake, g/day</td>
                        <td align="left" rowspan="1" colspan="1">3.1 (0.8–9.7)</td>
                        <td align="left" rowspan="1" colspan="1">3.4 (0.8–10.5)</td>
                        <td align="left" rowspan="1" colspan="1">4.7 (0.8–10.9)</td>
                        <td align="left" rowspan="1" colspan="1">5.2 (0.9–11.8)</td>
                        <td align="left" rowspan="1" colspan="1">&lt;0.001</td>
                      </tr>
                    </tbody>
                  </table>
                  <table-wrap-foot>
                    <fn id="jah32453-note-0003">
                      <p>Data are shown as mean±SD, percentage (number), or median (interquartile range). <italic>P</italic> for Jonckheere Terpstra test across categories. EPIC indicates European Prospective Investigation into Cancer; HDL, high‐density lipoprotein; LDL, low‐density lipoprotein.</p>
                    </fn>
                  </table-wrap-foot>
                </table-wrap>
                <table-wrap id="jah32453-tbl-0002" xml:lang="en" orientation="portrait" position="float">
                  <label>Table 2</label>
                  <caption>
                    <p>Baseline Characteristics by Apolipoprotein A‐I Quartiles in the EPIC‐Norfolk Study</p>
                  </caption>
                  <table frame="hsides" rules="groups">
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <thead valign="top">
                      <tr style="border-bottom:solid 1px #000000">
                        <th align="left" rowspan="2" valign="top" colspan="1"/>
                        <th align="left" colspan="4" style="border-bottom:solid 1px #000000" valign="top" rowspan="1">Apolipoprotein A‐I Quartiles</th>
                        <th align="left" rowspan="2" valign="top" colspan="1"><italic>P</italic> Value</th>
                      </tr>
                      <tr style="border-bottom:solid 1px #000000">
                        <th align="left" valign="top" rowspan="1" colspan="1">1</th>
                        <th align="left" valign="top" rowspan="1" colspan="1">2</th>
                        <th align="left" valign="top" rowspan="1" colspan="1">3</th>
                        <th align="left" valign="top" rowspan="1" colspan="1">4</th>
                      </tr>
                    </thead>
                    <tbody>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">N</td>
                        <td align="left" rowspan="1" colspan="1">4325</td>
                        <td align="left" rowspan="1" colspan="1">4514</td>
                        <td align="left" rowspan="1" colspan="1">4403</td>
                        <td align="left" rowspan="1" colspan="1">4419</td>
                        <td align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">HDL cholesterol, mmol/L</td>
                        <td align="left" rowspan="1" colspan="1">1.1±0.3</td>
                        <td align="left" rowspan="1" colspan="1">1.3±0.3</td>
                        <td align="left" rowspan="1" colspan="1">1.5±0.3</td>
                        <td align="left" rowspan="1" colspan="1">1.8±0.4</td>
                        <td align="left" rowspan="1" colspan="1">&lt;0.001</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Age, y</td>
                        <td align="left" rowspan="1" colspan="1">58.6±9.2</td>
                        <td align="left" rowspan="1" colspan="1">59.1±9.1</td>
                        <td align="left" rowspan="1" colspan="1">59.3±9.2</td>
                        <td align="left" rowspan="1" colspan="1">59.2</td>
                        <td align="left" rowspan="1" colspan="1">&lt;0.001</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Male sex</td>
                        <td align="left" rowspan="1" colspan="1">64% (2768)</td>
                        <td align="left" rowspan="1" colspan="1">56% (2528)</td>
                        <td align="left" rowspan="1" colspan="1">36% (1585)</td>
                        <td align="left" rowspan="1" colspan="1">21% (928)</td>
                        <td align="left" rowspan="1" colspan="1">&lt;0.001</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Body mass index, kg/m<sup>2</sup>
</td>
                        <td align="left" rowspan="1" colspan="1">26.6±3.7</td>
                        <td align="left" rowspan="1" colspan="1">26.4±3.7</td>
                        <td align="left" rowspan="1" colspan="1">26.1±3.9</td>
                        <td align="left" rowspan="1" colspan="1">25.5±3.7</td>
                        <td align="left" rowspan="1" colspan="1">&lt;0.001</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Diabetes mellitus, % (n)</td>
                        <td align="left" rowspan="1" colspan="1">2.9 (126)</td>
                        <td align="left" rowspan="1" colspan="1">2.3 (102)</td>
                        <td align="left" rowspan="1" colspan="1">1.8 (77)</td>
                        <td align="left" rowspan="1" colspan="1">1.2 (53)</td>
                        <td align="left" rowspan="1" colspan="1">&lt;0.001</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">HbA1c, %</td>
                        <td align="left" rowspan="1" colspan="1">5.3±0.8</td>
                        <td align="left" rowspan="1" colspan="1">5.3±0.9</td>
                        <td align="left" rowspan="1" colspan="1">5.3±0.8</td>
                        <td align="left" rowspan="1" colspan="1">5.3±0.8</td>
                        <td align="left" rowspan="1" colspan="1">0.66</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Systolic blood pressure, mm Hg</td>
                        <td align="left" rowspan="1" colspan="1">134±18</td>
                        <td align="left" rowspan="1" colspan="1">135±18</td>
                        <td align="left" rowspan="1" colspan="1">135±19</td>
                        <td align="left" rowspan="1" colspan="1">135±19</td>
                        <td align="left" rowspan="1" colspan="1">&lt;0.001</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Diastolic blood pressure, mm Hg</td>
                        <td align="left" rowspan="1" colspan="1">82±11</td>
                        <td align="left" rowspan="1" colspan="1">82±11</td>
                        <td align="left" rowspan="1" colspan="1">82±11</td>
                        <td align="left" rowspan="1" colspan="1">82±11</td>
                        <td align="left" rowspan="1" colspan="1">0.90</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Total cholesterol, mmol/L</td>
                        <td align="left" rowspan="1" colspan="1">5.9±1.1</td>
                        <td align="left" rowspan="1" colspan="1">6.1±1.1</td>
                        <td align="left" rowspan="1" colspan="1">6.2±1.1</td>
                        <td align="left" rowspan="1" colspan="1">6.4±1.1</td>
                        <td align="left" rowspan="1" colspan="1">&lt;0.001</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">LDL cholesterol, mmol/L</td>
                        <td align="left" rowspan="1" colspan="1">3.9±1.0</td>
                        <td align="left" rowspan="1" colspan="1">4.0±1.0</td>
                        <td align="left" rowspan="1" colspan="1">4.0±1.0</td>
                        <td align="left" rowspan="1" colspan="1">3.9±1.1</td>
                        <td align="left" rowspan="1" colspan="1">0.50</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Non‐HDL cholesterol, mmol/L</td>
                        <td align="left" rowspan="1" colspan="1">4.7±1.2</td>
                        <td align="left" rowspan="1" colspan="1">4.8±1.2</td>
                        <td align="left" rowspan="1" colspan="1">4.7±1.2</td>
                        <td align="left" rowspan="1" colspan="1">4.6±1.2</td>
                        <td align="left" rowspan="1" colspan="1">&lt;0.001</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Triglycerides, mmol/L</td>
                        <td align="left" rowspan="1" colspan="1">1.7 (1.2–2.4)</td>
                        <td align="left" rowspan="1" colspan="1">1.6 (1.1–2.2)</td>
                        <td align="left" rowspan="1" colspan="1">1.4 (1.0–2.0)</td>
                        <td align="left" rowspan="1" colspan="1">1.3 (0.9–1.8)</td>
                        <td align="left" rowspan="1" colspan="1">&lt;0.001</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Apolipoprotein A‐I, mg/dL</td>
                        <td align="left" rowspan="1" colspan="1">115±18</td>
                        <td align="left" rowspan="1" colspan="1">145±5</td>
                        <td align="left" rowspan="1" colspan="1">164±6</td>
                        <td align="left" rowspan="1" colspan="1">199±17</td>
                        <td align="left" rowspan="1" colspan="1">&lt;0.001</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Apolipoprotein B, mg/dL</td>
                        <td align="left" rowspan="1" colspan="1">88±27</td>
                        <td align="left" rowspan="1" colspan="1">100±23</td>
                        <td align="left" rowspan="1" colspan="1">99±23</td>
                        <td align="left" rowspan="1" colspan="1">99±23</td>
                        <td align="left" rowspan="1" colspan="1">&lt;0.001</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">C‐reactive protein, mg/L</td>
                        <td align="left" rowspan="1" colspan="1">1.9 (0.9–4.4)</td>
                        <td align="left" rowspan="1" colspan="1">1.8 (0.8–3.6)</td>
                        <td align="left" rowspan="1" colspan="1">1.5 (0.8–3.1)</td>
                        <td align="left" rowspan="1" colspan="1">1.5 (0.7–3.3)</td>
                        <td align="left" rowspan="1" colspan="1">&lt;0.001</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Metabolic syndrome</td>
                        <td align="left" rowspan="1" colspan="1">71% (3071)</td>
                        <td align="left" rowspan="1" colspan="1">78% (3521)</td>
                        <td align="left" rowspan="1" colspan="1">69% (3038)</td>
                        <td align="left" rowspan="1" colspan="1">55% (2431)</td>
                        <td align="left" rowspan="1" colspan="1">&lt;0.001</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Alcohol intake, g/day</td>
                        <td align="left" rowspan="1" colspan="1">3.1 (0.8–9.6)</td>
                        <td align="left" rowspan="1" colspan="1">4.7 (0.8–10.9)</td>
                        <td align="left" rowspan="1" colspan="1">4.1 (0.8–10.9)</td>
                        <td align="left" rowspan="1" colspan="1">5.1 (0.8–11.7)</td>
                        <td align="left" rowspan="1" colspan="1">&lt;0.001</td>
                      </tr>
                    </tbody>
                  </table>
                  <table-wrap-foot>
                    <fn id="jah32453-note-0004">
                      <p>Data are shown as mean±SD, percentage (number), or median (interquartile range). <italic>P</italic> for Jonckheere Terpstra trend test across categories. EPIC indicates European Prospective Investigation into Cancer; HDL, high‐density lipoprotein; LDL, low‐density lipoprotein.</p>
                    </fn>
                  </table-wrap-foot>
                </table-wrap>
                <sec id="jah32453-sec-0018">
                  <title>Risk of coronary heart disease across quartiles of HDL‐C and apoA‐I</title>
                  <p>Hazard ratios for risk of CHD by HDL‐C and apoA‐I quartiles are shown in Tables <xref rid="jah32453-tbl-0003" ref-type="table-wrap">3</xref> and <xref rid="jah32453-tbl-0004" ref-type="table-wrap">4</xref> and Figure <xref rid="jah32453-fig-0001" ref-type="fig">1</xref>. Among individuals in the top HDL‐C quartile, the hazard ratio for CHD events was 0.34 (95% CI 0.30–0.39) compared with those in the bottom HDL‐C quartile (<italic>P</italic> for linear trend &lt;0.001). In a fully adjusted model, the hazard ratio for CHD was 0.69 (95% CI 0.59–0.80) for those in the top versus bottom quartile (<italic>P</italic> for linear trend &lt;0.001).</p>
                  <table-wrap id="jah32453-tbl-0003" xml:lang="en" orientation="portrait" position="float">
                    <label>Table 3</label>
                    <caption>
                      <p>Risk of CHD Events by HDL Cholesterol Quartiles in the EPIC‐Norfolk Study</p>
                    </caption>
                    <table frame="hsides" rules="groups">
                      <col style="border-right:solid 1px #000000" span="1"/>
                      <col style="border-right:solid 1px #000000" span="1"/>
                      <col style="border-right:solid 1px #000000" span="1"/>
                      <col style="border-right:solid 1px #000000" span="1"/>
                      <col style="border-right:solid 1px #000000" span="1"/>
                      <col style="border-right:solid 1px #000000" span="1"/>
                      <thead valign="top">
                        <tr style="border-bottom:solid 1px #000000">
                          <th align="left" rowspan="3" valign="top" colspan="1"/>
                          <th align="left" colspan="4" style="border-bottom:solid 1px #000000" valign="top" rowspan="1">HDL Cholesterol Quartiles</th>
                          <th align="left" rowspan="3" valign="top" colspan="1"><italic>P</italic> Value</th>
                        </tr>
                        <tr style="border-bottom:solid 1px #000000">
                          <th align="left" style="border-bottom:solid 1px #000000" valign="top" rowspan="1" colspan="1">1</th>
                          <th align="left" style="border-bottom:solid 1px #000000" valign="top" rowspan="1" colspan="1">2</th>
                          <th align="left" style="border-bottom:solid 1px #000000" valign="top" rowspan="1" colspan="1">3</th>
                          <th align="left" style="border-bottom:solid 1px #000000" valign="top" rowspan="1" colspan="1">4</th>
                        </tr>
                        <tr style="border-bottom:solid 1px #000000">
                          <th align="left" valign="top" rowspan="1" colspan="1">&lt;1.1 mmol/L</th>
                          <th align="left" valign="top" rowspan="1" colspan="1">1.1 to 1.4 mmol/L</th>
                          <th align="left" valign="top" rowspan="1" colspan="1">1.4 to 1.7 mmol/L</th>
                          <th align="left" valign="top" rowspan="1" colspan="1">≥1.7 mmol/L</th>
                        </tr>
                      </thead>
                      <tbody>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">Cases/total</td>
                          <td align="left" rowspan="1" colspan="1">963/5031</td>
                          <td align="left" rowspan="1" colspan="1">479/3595</td>
                          <td align="left" rowspan="1" colspan="1">465/4444</td>
                          <td align="left" rowspan="1" colspan="1">319/4591</td>
                          <td align="left" rowspan="1" colspan="1"/>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">Model 1</td>
                          <td align="left" rowspan="1" colspan="1">1.00</td>
                          <td align="left" rowspan="1" colspan="1">0.67 (0.60–0.74)</td>
                          <td align="left" rowspan="1" colspan="1">0.52 (0.47–0.58)</td>
                          <td align="left" rowspan="1" colspan="1">0.34 (0.30–0.39)</td>
                          <td align="left" rowspan="1" colspan="1">&lt;0.001</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">Model 2</td>
                          <td align="left" rowspan="1" colspan="1">1.00</td>
                          <td align="left" rowspan="1" colspan="1">0.81 (0.73–0.91)</td>
                          <td align="left" rowspan="1" colspan="1">0.77 (0.69–0.87)</td>
                          <td align="left" rowspan="1" colspan="1">0.61 (0.53–0.71)</td>
                          <td align="left" rowspan="1" colspan="1">&lt;0.001</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">Model 3</td>
                          <td align="left" rowspan="1" colspan="1">1.00</td>
                          <td align="left" rowspan="1" colspan="1">0.85 (0.76–0.95)</td>
                          <td align="left" rowspan="1" colspan="1">0.83 (0.74–0.94)</td>
                          <td align="left" rowspan="1" colspan="1">0.69 (0.59–0.80)</td>
                          <td align="left" rowspan="1" colspan="1">&lt;0.001</td>
                        </tr>
                      </tbody>
                    </table>
                    <table-wrap-foot>
                      <fn id="jah32453-note-0005">
                        <p>Data are shown as hazard ratios and corresponding 95% CI for the risk of future coronary heart disease events. Hazard ratios were calculated by quartile, using the lowest quartile as reference category. P value is for trend across quartiles. Model 1 indicates an unadjusted regression model. Model 2 is adjusted for sex, age, smoking, body mass index, systolic blood pressure, apolipoprotein B, and C‐reactive protein. Model 3 is adjusted for the variables in model 2 and in addition for triglycerides. CHD indicates coronary heart disease; EPIC, European Prospective Investigation into Cancer; HDL, high‐density lipoprotein.</p>
                      </fn>
                    </table-wrap-foot>
                  </table-wrap>
                  <table-wrap id="jah32453-tbl-0004" xml:lang="en" orientation="portrait" position="float">
                    <label>Table 4</label>
                    <caption>
                      <p>Risk of CHD Events by Apolipoprotein A‐I Quartiles in the EPIC‐Norfolk Study</p>
                    </caption>
                    <table frame="hsides" rules="groups">
                      <col style="border-right:solid 1px #000000" span="1"/>
                      <col style="border-right:solid 1px #000000" span="1"/>
                      <col style="border-right:solid 1px #000000" span="1"/>
                      <col style="border-right:solid 1px #000000" span="1"/>
                      <col style="border-right:solid 1px #000000" span="1"/>
                      <col style="border-right:solid 1px #000000" span="1"/>
                      <thead valign="top">
                        <tr style="border-bottom:solid 1px #000000">
                          <th align="left" rowspan="3" valign="top" colspan="1"/>
                          <th align="left" colspan="4" style="border-bottom:solid 1px #000000" valign="top" rowspan="1">Apolipoprotein A‐I Quartiles</th>
                          <th align="left" rowspan="3" valign="top" colspan="1"><italic>P</italic> Value</th>
                        </tr>
                        <tr style="border-bottom:solid 1px #000000">
                          <th align="left" style="border-bottom:solid 1px #000000" valign="top" rowspan="1" colspan="1">1</th>
                          <th align="left" style="border-bottom:solid 1px #000000" valign="top" rowspan="1" colspan="1">2</th>
                          <th align="left" style="border-bottom:solid 1px #000000" valign="top" rowspan="1" colspan="1">3</th>
                          <th align="left" style="border-bottom:solid 1px #000000" valign="top" rowspan="1" colspan="1">4</th>
                        </tr>
                        <tr style="border-bottom:solid 1px #000000">
                          <th align="left" valign="top" rowspan="1" colspan="1">&lt;135 mg/dL</th>
                          <th align="left" valign="top" rowspan="1" colspan="1">135 to 154 mg/dL</th>
                          <th align="left" valign="top" rowspan="1" colspan="1">154 to 177 mg/dL</th>
                          <th align="left" valign="top" rowspan="1" colspan="1">≥177 mg/dL</th>
                        </tr>
                      </thead>
                      <tbody>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">Cases/total</td>
                          <td align="left" rowspan="1" colspan="1">701/4325</td>
                          <td align="left" rowspan="1" colspan="1">624/4514</td>
                          <td align="left" rowspan="1" colspan="1">494/4403</td>
                          <td align="left" rowspan="1" colspan="1">407/4419</td>
                          <td align="left" rowspan="1" colspan="1"/>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">Model 1</td>
                          <td align="left" rowspan="1" colspan="1">1.00</td>
                          <td align="left" rowspan="1" colspan="1">0.81 (0.73–0.90)</td>
                          <td align="left" rowspan="1" colspan="1">0.66 (0.59–0.74)</td>
                          <td align="left" rowspan="1" colspan="1">0.55 (0.49–0.62)</td>
                          <td align="left" rowspan="1" colspan="1">&lt;0.001</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">Model 2</td>
                          <td align="left" rowspan="1" colspan="1">1.00</td>
                          <td align="left" rowspan="1" colspan="1">0.77 (0.69–0.86)</td>
                          <td align="left" rowspan="1" colspan="1">0.74 (0.65–0.83)</td>
                          <td align="left" rowspan="1" colspan="1">0.69 (0.61–0.79)</td>
                          <td align="left" rowspan="1" colspan="1">&lt;0.001</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">Model 3</td>
                          <td align="left" rowspan="1" colspan="1">1.00</td>
                          <td align="left" rowspan="1" colspan="1">0.79 (0.71–0.89)</td>
                          <td align="left" rowspan="1" colspan="1">0.78 (0.69–0.88)</td>
                          <td align="left" rowspan="1" colspan="1">0.75 (0.66–0.86)</td>
                          <td align="left" rowspan="1" colspan="1">&lt;0.001</td>
                        </tr>
                      </tbody>
                    </table>
                    <table-wrap-foot>
                      <fn id="jah32453-note-0006">
                        <p>CHD indicates coronary heart disease; Data are shown as hazard ratios and corresponding 95% CI for the risk of future coronary heart disease events. Hazard ratios were calculated by quartile, using the lowest quartile as reference category. <italic>P</italic> value is for trend across quartiles. Model 1 indicates an unadjusted regression model. Model 2 is adjusted for sex, age, smoking, body mass index, systolic blood pressure, apolipoprotein B, and C‐reactive protein. Model 3 is adjusted for the variables in model 2 and in addition for triglycerides. CHD indicates coronary heart disease; EPIC, European Prospective Investigation into Cancer.</p>
                      </fn>
                    </table-wrap-foot>
                  </table-wrap>
                  <fig fig-type="Figure" xml:lang="en" id="jah32453-fig-0001" orientation="portrait" position="float">
                    <label>Figure 1</label>
                    <caption>
                      <p>Adjusted hazard ratios for coronary heart disease per <styled-content style="fixed-case">HDL</styled-content>‐C (A) and apolipoprotein A‐I (B) quartile in the <styled-content style="fixed-case">EPIC</styled-content>‐Norfolk Study. Data are shown as hazard ratios and corresponding 95% CI for the risk of future coronary heart disease events. Hazard ratios were calculated by quartile, using the lowest quartile as reference category, and were adjusted for sex, age, smoking, body mass index, systolic blood pressure, apolipoprotein B, C‐reactive protein, and triglyceride levels. ApoA‐I indicates apolipoprotein A‐I; EPIC, European Prospective Investigation into Cancer; <styled-content style="fixed-case">HDL</styled-content>‐C, high‐density lipoprotein cholesterol.</p>
                    </caption>
                    <graphic id="nlm-graphic-1" xlink:href="JAH3-6-e006636-g001"/>
                  </fig>
                  <p>Individuals in the top quartile for apoA‐I had a hazard ratio for CHD events of 0.55 (95% CI 0.49–0.62, <italic>P</italic> for linear trend &lt;0.001) using an unadjusted model. In a fully adjusted model the hazard ratio was 0.75 (95% CI 0.66–0.86, <italic>P</italic> for linear trend &lt;0.001).</p>
                  <p>Table <xref rid="jah32453-tbl-0005" ref-type="table-wrap">5</xref> shows the distribution of participants, CHD event rates, and hazard ratio and corresponding 95% CI across HDL‐C and apoA‐I quartiles. The event‐free survival curves per HDL‐C and apoA‐I quartile are shown in Figure <xref rid="jah32453-fig-0002" ref-type="fig">2</xref>. In the majority of study participants (n=9478, 54%), HDL‐C quartiles corresponded with apoA‐I quartiles. However, for 8183 participants, the HDL‐C quartile and apoA‐I quartile were discordant.</p>
                  <table-wrap id="jah32453-tbl-0005" xml:lang="en" orientation="portrait" position="float">
                    <label>Table 5</label>
                    <caption>
                      <p>Risk of CHD Events by HDL Cholesterol and Apolipoprotein A‐I Quartiles in the EPIC‐Norfolk Study</p>
                    </caption>
                    <table frame="hsides" rules="groups">
                      <col style="border-right:solid 1px #000000" span="1"/>
                      <col style="border-right:solid 1px #000000" span="1"/>
                      <col style="border-right:solid 1px #000000" span="1"/>
                      <col style="border-right:solid 1px #000000" span="1"/>
                      <col style="border-right:solid 1px #000000" span="1"/>
                      <col style="border-right:solid 1px #000000" span="1"/>
                      <thead valign="top">
                        <tr style="border-bottom:solid 1px #000000">
                          <th align="left" rowspan="2" valign="top" colspan="1"/>
                          <th align="left" colspan="4" style="border-bottom:solid 1px #000000" valign="top" rowspan="1">HDL Cholesterol Quartiles</th>
                          <th align="left" rowspan="2" valign="top" colspan="1"><italic>P</italic> Value</th>
                        </tr>
                        <tr style="border-bottom:solid 1px #000000">
                          <th align="left" valign="top" rowspan="1" colspan="1">1</th>
                          <th align="left" valign="top" rowspan="1" colspan="1">2</th>
                          <th align="left" valign="top" rowspan="1" colspan="1">3</th>
                          <th align="left" valign="top" rowspan="1" colspan="1">4</th>
                        </tr>
                      </thead>
                      <tbody>
                        <tr>
                          <td align="left" colspan="6" rowspan="1">ApoA‐I quartiles</td>
                        </tr>
                        <tr>
                          <td align="left" style="padding-left:10%" rowspan="2" colspan="1">1</td>
                          <td align="left" rowspan="1" colspan="1">572/2923</td>
                          <td align="left" rowspan="1" colspan="1">77/615</td>
                          <td align="left" rowspan="1" colspan="1">36/476</td>
                          <td align="left" rowspan="1" colspan="1">16/302</td>
                          <td align="left" rowspan="1" colspan="1">&lt;0.001</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">1.00</td>
                          <td align="left" rowspan="1" colspan="1">0.86 (0.67–1.09)</td>
                          <td align="left" rowspan="1" colspan="1">0.61 (0.43–0.85)</td>
                          <td align="left" rowspan="1" colspan="1">0.47 (0.28–0.78)</td>
                          <td align="left" rowspan="1" colspan="1"/>
                        </tr>
                        <tr>
                          <td align="left" style="padding-left:10%" rowspan="2" colspan="1">2</td>
                          <td align="left" rowspan="1" colspan="1">301/1605</td>
                          <td align="left" rowspan="1" colspan="1">214/1658</td>
                          <td align="left" rowspan="1" colspan="1">97/978</td>
                          <td align="left" rowspan="1" colspan="1">12/273</td>
                          <td align="left" rowspan="1" colspan="1">&lt;0.001</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">0.91 (0.79–1.05)</td>
                          <td align="left" rowspan="1" colspan="1">0.69 (0.59–0.81)</td>
                          <td align="left" rowspan="1" colspan="1">0.65 (0.52–0.81)</td>
                          <td align="left" rowspan="1" colspan="1">0.35 (0.19–0.63)</td>
                          <td align="left" rowspan="1" colspan="1"/>
                        </tr>
                        <tr>
                          <td align="left" style="padding-left:10%" rowspan="2" colspan="1">3</td>
                          <td align="left" rowspan="1" colspan="1">72/397</td>
                          <td align="left" rowspan="1" colspan="1">143/1039</td>
                          <td align="left" rowspan="1" colspan="1">199/1924</td>
                          <td align="left" rowspan="1" colspan="1">80/1043</td>
                          <td align="left" rowspan="1" colspan="1">&lt;0.001</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">0.88 (0.68–1.12)</td>
                          <td align="left" rowspan="1" colspan="1">0.75 (0.63–0.91)</td>
                          <td align="left" rowspan="1" colspan="1">0.69 (0.59–0.82)</td>
                          <td align="left" rowspan="1" colspan="1">0.59 (0.46–0.75)</td>
                          <td align="left" rowspan="1" colspan="1"/>
                        </tr>
                        <tr>
                          <td align="left" style="padding-left:10%" rowspan="2" colspan="1">4</td>
                          <td align="left" rowspan="1" colspan="1">18/97</td>
                          <td align="left" rowspan="1" colspan="1">45/283</td>
                          <td align="left" rowspan="1" colspan="1">133/1066</td>
                          <td align="left" rowspan="1" colspan="1">211/2973</td>
                          <td align="left" rowspan="1" colspan="1">&lt;0.001</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">0.87 (0.54–1.40)</td>
                          <td align="left" rowspan="1" colspan="1">0.93 (0.68–1.26)</td>
                          <td align="left" rowspan="1" colspan="1">0.81 (0.67–0.99)</td>
                          <td align="left" rowspan="1" colspan="1">0.57 (0.48–0.67)</td>
                          <td align="left" rowspan="1" colspan="1"/>
                        </tr>
                        <tr>
                          <td align="left" style="padding-left:10%" rowspan="1" colspan="1"><italic>P</italic> value</td>
                          <td align="left" rowspan="1" colspan="1">0.41</td>
                          <td align="left" rowspan="1" colspan="1">0.18</td>
                          <td align="left" rowspan="1" colspan="1">0.005</td>
                          <td align="left" rowspan="1" colspan="1">0.35</td>
                          <td align="left" rowspan="1" colspan="1"/>
                        </tr>
                      </tbody>
                    </table>
                    <table-wrap-foot>
                      <fn id="jah32453-note-0007">
                        <p>Data are shown as number of coronary heart disease events/total number of study participants and unadjusted hazard ratios and corresponding 95% CI. Hazard ratios were calculated using those in the bottom quartiles for both HDL cholesterol and apolipoprotein A‐I as reference category. ApoA‐I indicates apolipoprotein A‐I; CHD, coronary heart disease EPIC, European Prospective Investigation into Cancer; HDL, high‐density lipoprotein.</p>
                      </fn>
                    </table-wrap-foot>
                  </table-wrap>
                  <fig fig-type="Figure" xml:lang="en" id="jah32453-fig-0002" orientation="portrait" position="float">
                    <label>Figure 2</label>
                    <caption>
                      <p>Kaplan–Meier event‐free survival curves per <styled-content style="fixed-case">HDL</styled-content> cholesterol and apolipoprotein A‐I quartile in the <styled-content style="fixed-case">EPIC</styled-content>‐Norfolk Study. ApoA‐I indicates apolipoprotein A‐I; EPIC, European Prospective Investigation into Cancer; <styled-content style="fixed-case">HDL</styled-content>‐C, high‐density lipoprotein cholesterol.</p>
                    </caption>
                    <graphic id="nlm-graphic-3" xlink:href="JAH3-6-e006636-g002"/>
                  </fig>
                  <p>Compared with study participants in the bottom quartiles for both HDL‐C and apoA‐I, those in the second, third, and top quartiles for both HDL‐C and apoA‐I had a hazard ratio (HR) of 0.69 (95% CI 0.59–0.81), HR 0.69 (95% CI 0.59–0.82), and HR 0.57 (95% CI 0.48–0.67), respectively. Those in the lowest HDL‐C quartile and the top apoA‐I quartile were not at lower CHD risk (HR 0.87, 95% CI 0.54–1.40). By contrast, those in the top HDL‐C quartile but the bottom apoA‐I quartile were at lower CHD risk (HR 0.47, 95% CI 0.28–0.78), and this hazard ratio was even lower than the participants having both high HDL‐C and high apoA‐I levels (HR 0.57, 95% CI 0.48–0.67). Within each apoA‐I quartile, higher HDL‐C levels were associated with lower CHD risk. By contrast, within each HDL‐C quartile, we did not find a consistent association between apoA‐I and CHD risk. A trend towards increased CHD risk for higher apoA‐I levels in the middle HDL‐C quartiles was observed, which was significant in the third HDL‐C quartile (<italic>P</italic>=0.005).</p>
                </sec>
                <sec id="jah32453-sec-0019">
                  <title>Distribution of risk factors across quartiles of HDL‐C and apoA‐I</title>
                  <p>The distribution of risk factors across HDL‐C and apoA‐I quartiles is presented in Table <xref rid="jah32453-tbl-0006" ref-type="table-wrap">6</xref>. Within fixed apoA‐I quartiles, HDL‐C levels were inversely associated with CHD risk factors (all <italic>P</italic>&lt;0.001). However, the opposite pattern was observed for apoA‐I levels within fixed HDL‐C quartiles. Here, apoA‐I levels were positively associated with age, female sex, body mass index, HbA1c, non‐HDL‐C, triglycerides, apoB, systolic blood pressure, and CRP (all <italic>P</italic>&lt;0.001). Overall, groups defined by high HDL‐C and low apoA‐I levels consisted of relatively healthy subjects, compared with subjects defined by low HDL‐C and high apoA‐I levels, where enrichment for traditional CHD risk factors was observed.</p>
                  <table-wrap id="jah32453-tbl-0006" xml:lang="en" orientation="portrait" position="float">
                    <label>Table 6</label>
                    <caption>
                      <p>Baseline Characteristics by HDL‐C and apoA‐I Quartiles in the EPIC‐Norfolk Study</p>
                    </caption>
                    <table frame="hsides" rules="groups">
                      <col style="border-right:solid 1px #000000" span="1"/>
                      <col style="border-right:solid 1px #000000" span="1"/>
                      <col style="border-right:solid 1px #000000" span="1"/>
                      <col style="border-right:solid 1px #000000" span="1"/>
                      <col style="border-right:solid 1px #000000" span="1"/>
                      <col style="border-right:solid 1px #000000" span="1"/>
                      <col style="border-right:solid 1px #000000" span="1"/>
                      <thead valign="top">
                        <tr style="border-bottom:solid 1px #000000">
                          <th align="left" rowspan="2" valign="top" colspan="1"/>
                          <th align="left" rowspan="2" valign="top" colspan="1">ApoA‐I Quartiles</th>
                          <th align="left" colspan="4" style="border-bottom:solid 1px #000000" valign="top" rowspan="1">HDL Cholesterol Quartiles</th>
                          <th align="left" rowspan="2" valign="top" colspan="1"><italic>P</italic> Value</th>
                        </tr>
                        <tr style="border-bottom:solid 1px #000000">
                          <th align="left" valign="top" rowspan="1" colspan="1">1</th>
                          <th align="left" valign="top" rowspan="1" colspan="1">2</th>
                          <th align="left" valign="top" rowspan="1" colspan="1">3</th>
                          <th align="left" valign="top" rowspan="1" colspan="1">4</th>
                        </tr>
                      </thead>
                      <tbody>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">Apolipoprotein A‐I, mg/dL</td>
                          <td align="left" rowspan="1" colspan="1">1</td>
                          <td align="left" rowspan="1" colspan="1">116±17 (2909)</td>
                          <td align="left" rowspan="1" colspan="1">113±21 (604)</td>
                          <td align="left" rowspan="1" colspan="1">108±20 (456)</td>
                          <td align="left" rowspan="1" colspan="1">111±18 (289)</td>
                          <td align="left" rowspan="1" colspan="1">&lt;0.001</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1"/>
                          <td align="left" rowspan="1" colspan="1">2</td>
                          <td align="left" rowspan="1" colspan="1">143±5 (1605)</td>
                          <td align="left" rowspan="1" colspan="1">146±6 (1658)</td>
                          <td align="left" rowspan="1" colspan="1">147±5 (978)</td>
                          <td align="left" rowspan="1" colspan="1">147±6 (273)</td>
                          <td align="left" rowspan="1" colspan="1">&lt;0.001</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1"/>
                          <td align="left" rowspan="1" colspan="1">3</td>
                          <td align="left" rowspan="1" colspan="1">163±6 (397)</td>
                          <td align="left" rowspan="1" colspan="1">163±6 (1039)</td>
                          <td align="left" rowspan="1" colspan="1">165±6 (1924)</td>
                          <td align="left" rowspan="1" colspan="1">167±6 (1043)</td>
                          <td align="left" rowspan="1" colspan="1">&lt;0.001</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1"/>
                          <td align="left" rowspan="1" colspan="1">4</td>
                          <td align="left" rowspan="1" colspan="1">189±14 (97)</td>
                          <td align="left" rowspan="1" colspan="1">191±13 (282)</td>
                          <td align="left" rowspan="1" colspan="1">192±14 (1061)</td>
                          <td align="left" rowspan="1" colspan="1">202±18 (2863)</td>
                          <td align="left" rowspan="1" colspan="1">&lt;0.001</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1"><italic>P</italic> value</td>
                          <td align="left" rowspan="1" colspan="1"/>
                          <td align="left" rowspan="1" colspan="1">&lt;0.001</td>
                          <td align="left" rowspan="1" colspan="1">&lt;0.001</td>
                          <td align="left" rowspan="1" colspan="1">&lt;0.001</td>
                          <td align="left" rowspan="1" colspan="1">&lt;0.001</td>
                          <td align="left" rowspan="1" colspan="1"/>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">HDL cholesterol, mmol/L</td>
                          <td align="left" rowspan="1" colspan="1">1</td>
                          <td align="left" rowspan="1" colspan="1">0.93±1.13 (2932)</td>
                          <td align="left" rowspan="1" colspan="1">1.24±0.05 (615)</td>
                          <td align="left" rowspan="1" colspan="1">1.48±0.08 (476)</td>
                          <td align="left" rowspan="1" colspan="1">1.9±0.32 (302)</td>
                          <td align="left" rowspan="1" colspan="1">&lt;0.001</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1"/>
                          <td align="left" rowspan="1" colspan="1">2</td>
                          <td align="left" rowspan="1" colspan="1">1.03±0.09 (1605)</td>
                          <td align="left" rowspan="1" colspan="1">1.25±0.05 (1658)</td>
                          <td align="left" rowspan="1" colspan="1">1.46±0.08 (978)</td>
                          <td align="left" rowspan="1" colspan="1">1.88±0.23 (273)</td>
                          <td align="left" rowspan="1" colspan="1">&lt;0.001</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1"/>
                          <td align="left" rowspan="1" colspan="1">3</td>
                          <td align="left" rowspan="1" colspan="1">1.04±0.09 (397)</td>
                          <td align="left" rowspan="1" colspan="1">1.26±0.05 (1039)</td>
                          <td align="left" rowspan="1" colspan="1">1.49±0.08 (1924)</td>
                          <td align="left" rowspan="1" colspan="1">1.86±0.18 (1043)</td>
                          <td align="left" rowspan="1" colspan="1">&lt;0.001</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1"/>
                          <td align="left" rowspan="1" colspan="1">4</td>
                          <td align="left" rowspan="1" colspan="1">1.03±0.10 (97)</td>
                          <td align="left" rowspan="1" colspan="1">1.26±0.05 (283)</td>
                          <td align="left" rowspan="1" colspan="1">1.52±0.08 (1066)</td>
                          <td align="left" rowspan="1" colspan="1">2.05±0.30 (2973)</td>
                          <td align="left" rowspan="1" colspan="1">&lt;0.001</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1"><italic>P</italic> value</td>
                          <td align="left" rowspan="1" colspan="1"/>
                          <td align="left" rowspan="1" colspan="1">&lt;0.001</td>
                          <td align="left" rowspan="1" colspan="1">&lt;0.001</td>
                          <td align="left" rowspan="1" colspan="1">&lt;0.001</td>
                          <td align="left" rowspan="1" colspan="1">&lt;0.001</td>
                          <td align="left" rowspan="1" colspan="1"/>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">Age, y</td>
                          <td align="left" rowspan="1" colspan="1">1</td>
                          <td align="left" rowspan="1" colspan="1">59.1±9.1 (2932)</td>
                          <td align="left" rowspan="1" colspan="1">57.5±9.0 (615)</td>
                          <td align="left" rowspan="1" colspan="1">57.6±9.2 (476)</td>
                          <td align="left" rowspan="1" colspan="1">57.4±9.4 (302)</td>
                          <td align="left" rowspan="1" colspan="1">&lt;0.001</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1"/>
                          <td align="left" rowspan="1" colspan="1">2</td>
                          <td align="left" rowspan="1" colspan="1">60±9.0 (1605)</td>
                          <td align="left" rowspan="1" colspan="1">59±9.0 (1658)</td>
                          <td align="left" rowspan="1" colspan="1">58.1±9.1 (978)</td>
                          <td align="left" rowspan="1" colspan="1">57.2±9.3 (273)</td>
                          <td align="left" rowspan="1" colspan="1">&lt;0.001</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1"/>
                          <td align="left" rowspan="1" colspan="1">3</td>
                          <td align="left" rowspan="1" colspan="1">60.7±9.0 (397)</td>
                          <td align="left" rowspan="1" colspan="1">60.1±9.1 (1039)</td>
                          <td align="left" rowspan="1" colspan="1">59.1±9.0 (1924)</td>
                          <td align="left" rowspan="1" colspan="1">58.3±9.4 (1043)</td>
                          <td align="left" rowspan="1" colspan="1">&lt;0.001</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1"/>
                          <td align="left" rowspan="1" colspan="1">4</td>
                          <td align="left" rowspan="1" colspan="1">61.1±8.6 (97)</td>
                          <td align="left" rowspan="1" colspan="1">60.8±8.8 (283)</td>
                          <td align="left" rowspan="1" colspan="1">60.1±9.2 (1066)</td>
                          <td align="left" rowspan="1" colspan="1">59.3±9.3 (2973)</td>
                          <td align="left" rowspan="1" colspan="1">&lt;0.001</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1"><italic>P</italic> value</td>
                          <td align="left" rowspan="1" colspan="1"/>
                          <td align="left" rowspan="1" colspan="1">&lt;0.001</td>
                          <td align="left" rowspan="1" colspan="1">&lt;0.001</td>
                          <td align="left" rowspan="1" colspan="1">&lt;0.001</td>
                          <td align="left" rowspan="1" colspan="1">&lt;0.001</td>
                          <td align="left" rowspan="1" colspan="1"/>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">Male sex</td>
                          <td align="left" rowspan="1" colspan="1">1</td>
                          <td align="left" rowspan="1" colspan="1">75.5 (2214/2932)</td>
                          <td align="left" rowspan="1" colspan="1">50.6 (311/615)</td>
                          <td align="left" rowspan="1" colspan="1">33.6 (160/476)</td>
                          <td align="left" rowspan="1" colspan="1">22.8 (69/302)</td>
                          <td align="left" rowspan="1" colspan="1">&lt;0.001</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1"/>
                          <td align="left" rowspan="1" colspan="1">2</td>
                          <td align="left" rowspan="1" colspan="1">67.5 (1083/1605)</td>
                          <td align="left" rowspan="1" colspan="1">57.0 (945/1658)</td>
                          <td align="left" rowspan="1" colspan="1">44.0 (430/978)</td>
                          <td align="left" rowspan="1" colspan="1">22.3 (61/273)</td>
                          <td align="left" rowspan="1" colspan="1">&lt;0.001</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1"/>
                          <td align="left" rowspan="1" colspan="1">3</td>
                          <td align="left" rowspan="1" colspan="1">52.9 (210/397)</td>
                          <td align="left" rowspan="1" colspan="1">44.7 (464/1039)</td>
                          <td align="left" rowspan="1" colspan="1">34.6 (665/1924)</td>
                          <td align="left" rowspan="1" colspan="1">24.6 (257/1043)</td>
                          <td align="left" rowspan="1" colspan="1">&lt;0.001</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1"/>
                          <td align="left" rowspan="1" colspan="1">4</td>
                          <td align="left" rowspan="1" colspan="1">46.4 (45/97)</td>
                          <td align="left" rowspan="1" colspan="1">40.6 (115/283)</td>
                          <td align="left" rowspan="1" colspan="1">27.3 (291/775)</td>
                          <td align="left" rowspan="1" colspan="1">15.6 (464/2973)</td>
                          <td align="left" rowspan="1" colspan="1">&lt;0.001</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1"><italic>P</italic> value</td>
                          <td align="left" rowspan="1" colspan="1"/>
                          <td align="left" rowspan="1" colspan="1">&lt;0.001</td>
                          <td align="left" rowspan="1" colspan="1">&lt;0.001</td>
                          <td align="left" rowspan="1" colspan="1">&lt;0.001</td>
                          <td align="left" rowspan="1" colspan="1">&lt;0.001</td>
                          <td align="left" rowspan="1" colspan="1"/>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">Body mass index, kg/m<sup>2</sup>
</td>
                          <td align="left" rowspan="1" colspan="1">1</td>
                          <td align="left" rowspan="1" colspan="1">27.1±3.6 (2926)</td>
                          <td align="left" rowspan="1" colspan="1">26.2±3.7 (614)</td>
                          <td align="left" rowspan="1" colspan="1">25.4±3.7 (475)</td>
                          <td align="left" rowspan="1" colspan="1">24.7±3.5 (302)</td>
                          <td align="left" rowspan="1" colspan="1">&lt;0.001</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1"/>
                          <td align="left" rowspan="1" colspan="1">2</td>
                          <td align="left" rowspan="1" colspan="1">27.3±3.7 (1600)</td>
                          <td align="left" rowspan="1" colspan="1">26.2±3.4 (1657)</td>
                          <td align="left" rowspan="1" colspan="1">25.5±3.5 (977)</td>
                          <td align="left" rowspan="1" colspan="1">25.1±4.0 (273)</td>
                          <td align="left" rowspan="1" colspan="1">&lt;0.001</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1"/>
                          <td align="left" rowspan="1" colspan="1">3</td>
                          <td align="left" rowspan="1" colspan="1">28±4.2 (396)</td>
                          <td align="left" rowspan="1" colspan="1">27.1±3.9 (1039)</td>
                          <td align="left" rowspan="1" colspan="1">26±3.8 (1923)</td>
                          <td align="left" rowspan="1" colspan="1">24.7±3.3 (1042)</td>
                          <td align="left" rowspan="1" colspan="1">&lt;0.001</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1"/>
                          <td align="left" rowspan="1" colspan="1">4</td>
                          <td align="left" rowspan="1" colspan="1">28.3±3.8 (97)</td>
                          <td align="left" rowspan="1" colspan="1">27.3±3.9 (283)</td>
                          <td align="left" rowspan="1" colspan="1">26.5±3.8 (1064)</td>
                          <td align="left" rowspan="1" colspan="1">24.9±3.5 (2967)</td>
                          <td align="left" rowspan="1" colspan="1">&lt;0.001</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1"><italic>P</italic> value</td>
                          <td align="left" rowspan="1" colspan="1"/>
                          <td align="left" rowspan="1" colspan="1">&lt;0.001</td>
                          <td align="left" rowspan="1" colspan="1">&lt;0.001</td>
                          <td align="left" rowspan="1" colspan="1">&lt;0.001</td>
                          <td align="left" rowspan="1" colspan="1">0.28</td>
                          <td align="left" rowspan="1" colspan="1"/>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">HbA1c, %</td>
                          <td align="left" rowspan="1" colspan="1">1</td>
                          <td align="left" rowspan="1" colspan="1">5.4±0.9 (1059)</td>
                          <td align="left" rowspan="1" colspan="1">5.2±0.7 (318)</td>
                          <td align="left" rowspan="1" colspan="1">5.3±0.8 (341)</td>
                          <td align="left" rowspan="1" colspan="1">5.2±0.8 (228)</td>
                          <td align="left" rowspan="1" colspan="1">0.001</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1"/>
                          <td align="left" rowspan="1" colspan="1">2</td>
                          <td align="left" rowspan="1" colspan="1">5.4±1.0 (615)</td>
                          <td align="left" rowspan="1" colspan="1">5.3±0.8 (476)</td>
                          <td align="left" rowspan="1" colspan="1">5.3±1.0 (238)</td>
                          <td align="left" rowspan="1" colspan="1">5.2±0.8 (140)</td>
                          <td align="left" rowspan="1" colspan="1">&lt;0.001</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1"/>
                          <td align="left" rowspan="1" colspan="1">3</td>
                          <td align="left" rowspan="1" colspan="1">5.7±1.2 (207)</td>
                          <td align="left" rowspan="1" colspan="1">5.3±0.8 (479)</td>
                          <td align="left" rowspan="1" colspan="1">5.3±0.8 (737)</td>
                          <td align="left" rowspan="1" colspan="1">5.2±0.7 (304)</td>
                          <td align="left" rowspan="1" colspan="1">&lt;0.001</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1"/>
                          <td align="left" rowspan="1" colspan="1">4</td>
                          <td align="left" rowspan="1" colspan="1">6±1.5 (54)</td>
                          <td align="left" rowspan="1" colspan="1">5.6±0.7 (166)</td>
                          <td align="left" rowspan="1" colspan="1">5.3±0.7 (574)</td>
                          <td align="left" rowspan="1" colspan="1">5.3±0.7 (1499)</td>
                          <td align="left" rowspan="1" colspan="1">&lt;0.001</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1"><italic>P</italic> value</td>
                          <td align="left" rowspan="1" colspan="1"/>
                          <td align="left" rowspan="1" colspan="1">0.001</td>
                          <td align="left" rowspan="1" colspan="1">&lt;0.001</td>
                          <td align="left" rowspan="1" colspan="1">0.34</td>
                          <td align="left" rowspan="1" colspan="1">0.01</td>
                          <td align="left" rowspan="1" colspan="1"/>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">Non‐HDL cholesterol, mmol/L</td>
                          <td align="left" rowspan="1" colspan="1">1</td>
                          <td align="left" rowspan="1" colspan="1">4.9±1.1 (2932)</td>
                          <td align="left" rowspan="1" colspan="1">4.6±1.1 (615)</td>
                          <td align="left" rowspan="1" colspan="1">4.5±1.2 (476)</td>
                          <td align="left" rowspan="1" colspan="1">4±1.0 (302)</td>
                          <td align="left" rowspan="1" colspan="1">&lt;0.001</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1"/>
                          <td align="left" rowspan="1" colspan="1">2</td>
                          <td align="left" rowspan="1" colspan="1">5.2±1.1 (1605)</td>
                          <td align="left" rowspan="1" colspan="1">4.9±1.1 (1658)</td>
                          <td align="left" rowspan="1" colspan="1">4.4±1.1 (978)</td>
                          <td align="left" rowspan="1" colspan="1">4.1±1.1 (273)</td>
                          <td align="left" rowspan="1" colspan="1">&lt;0.001</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1"/>
                          <td align="left" rowspan="1" colspan="1">3</td>
                          <td align="left" rowspan="1" colspan="1">5.3±1.2 (397)</td>
                          <td align="left" rowspan="1" colspan="1">5.1±1.1 (1039)</td>
                          <td align="left" rowspan="1" colspan="1">4.7±1.1 (1924)</td>
                          <td align="left" rowspan="1" colspan="1">4.3±1.2 (1043)</td>
                          <td align="left" rowspan="1" colspan="1">&lt;0.001</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1"/>
                          <td align="left" rowspan="1" colspan="1">4</td>
                          <td align="left" rowspan="1" colspan="1">5.6±1.2 (97)</td>
                          <td align="left" rowspan="1" colspan="1">5.2±1.1 (283)</td>
                          <td align="left" rowspan="1" colspan="1">5±1.1 (1066)</td>
                          <td align="left" rowspan="1" colspan="1">4.3±1.1 (2973)</td>
                          <td align="left" rowspan="1" colspan="1">&lt;0.001</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1"><italic>P</italic> value</td>
                          <td align="left" rowspan="1" colspan="1"/>
                          <td align="left" rowspan="1" colspan="1">&lt;0.001</td>
                          <td align="left" rowspan="1" colspan="1">&lt;0.001</td>
                          <td align="left" rowspan="1" colspan="1">&lt;0.001</td>
                          <td align="left" rowspan="1" colspan="1">&lt;0.001</td>
                          <td align="left" rowspan="1" colspan="1"/>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">Triglycerides, mmol/L</td>
                          <td align="left" rowspan="1" colspan="1">1</td>
                          <td align="left" rowspan="1" colspan="1">2.0 (1.4–2.7) (2932)</td>
                          <td align="left" rowspan="1" colspan="1">1.4 (1.0–1.9) (615)</td>
                          <td align="left" rowspan="1" colspan="1">1.3 (1.0–1.8) (476)</td>
                          <td align="left" rowspan="1" colspan="1">1.0 (0.8–1.4) (302)</td>
                          <td align="left" rowspan="1" colspan="1">&lt;0.001</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1"/>
                          <td align="left" rowspan="1" colspan="1">2</td>
                          <td align="left" rowspan="1" colspan="1">2.1 (1.5–2.7) (1605)</td>
                          <td align="left" rowspan="1" colspan="1">1.6 (1.1–2.1) (1658)</td>
                          <td align="left" rowspan="1" colspan="1">1.2 (0.9–1.6) (978)</td>
                          <td align="left" rowspan="1" colspan="1">1.0 (0.8–1.4) (273)</td>
                          <td align="left" rowspan="1" colspan="1">&lt;0.001</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1"/>
                          <td align="left" rowspan="1" colspan="1">3</td>
                          <td align="left" rowspan="1" colspan="1">2.3 (1.7–2.9) (397)</td>
                          <td align="left" rowspan="1" colspan="1">1.9 (1.4–2.4) (1039)</td>
                          <td align="left" rowspan="1" colspan="1">1.4 (1.0–1.8) (1924)</td>
                          <td align="left" rowspan="1" colspan="1">1.1 (0.8–1.4) (1043)</td>
                          <td align="left" rowspan="1" colspan="1">&lt;0.001</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1"/>
                          <td align="left" rowspan="1" colspan="1">4</td>
                          <td align="left" rowspan="1" colspan="1">2.4 (1.7–3.1) (97)</td>
                          <td align="left" rowspan="1" colspan="1">2.1 (1.5–2.7) (283)</td>
                          <td align="left" rowspan="1" colspan="1">1.6 (1.2–2.2) (1066)</td>
                          <td align="left" rowspan="1" colspan="1">1.1 (0.9–1.5) (2973)</td>
                          <td align="left" rowspan="1" colspan="1">&lt;0.001</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1"><italic>P</italic> value</td>
                          <td align="left" rowspan="1" colspan="1"/>
                          <td align="left" rowspan="1" colspan="1">&lt;0.001</td>
                          <td align="left" rowspan="1" colspan="1">&lt;0.001</td>
                          <td align="left" rowspan="1" colspan="1">&lt;0.001</td>
                          <td align="left" rowspan="1" colspan="1">&lt;0.001</td>
                          <td align="left" rowspan="1" colspan="1"/>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">Apolipoprotein B, mg/dL</td>
                          <td align="left" rowspan="1" colspan="1">1</td>
                          <td align="left" rowspan="1" colspan="1">96±25 (2871)</td>
                          <td align="left" rowspan="1" colspan="1">79±23 (577)</td>
                          <td align="left" rowspan="1" colspan="1">66±19 (415)</td>
                          <td align="left" rowspan="1" colspan="1">59±16 (241)</td>
                          <td align="left" rowspan="1" colspan="1">&lt;0.001</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1"/>
                          <td align="left" rowspan="1" colspan="1">2</td>
                          <td align="left" rowspan="1" colspan="1">106±23 (1601)</td>
                          <td align="left" rowspan="1" colspan="1">101±22 (1653)</td>
                          <td align="left" rowspan="1" colspan="1">94±21 (975)</td>
                          <td align="left" rowspan="1" colspan="1">76±21 (271)</td>
                          <td align="left" rowspan="1" colspan="1">&lt;0.001</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1"/>
                          <td align="left" rowspan="1" colspan="1">3</td>
                          <td align="left" rowspan="1" colspan="1">109±22 (394)</td>
                          <td align="left" rowspan="1" colspan="1">105±23 (1035)</td>
                          <td align="left" rowspan="1" colspan="1">99±22 (1915)</td>
                          <td align="left" rowspan="1" colspan="1">92±22 (1038)</td>
                          <td align="left" rowspan="1" colspan="1">&lt;0.001</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1"/>
                          <td align="left" rowspan="1" colspan="1">4</td>
                          <td align="left" rowspan="1" colspan="1">116±23 (95)</td>
                          <td align="left" rowspan="1" colspan="1">109±23 (282)</td>
                          <td align="left" rowspan="1" colspan="1">105±22 (1059)</td>
                          <td align="left" rowspan="1" colspan="1">96±22 (2958)</td>
                          <td align="left" rowspan="1" colspan="1">&lt;0.001</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1"><italic>P</italic> value</td>
                          <td align="left" rowspan="1" colspan="1"/>
                          <td align="left" rowspan="1" colspan="1">&lt;0.001</td>
                          <td align="left" rowspan="1" colspan="1">&lt;0.001</td>
                          <td align="left" rowspan="1" colspan="1">&lt;0.001</td>
                          <td align="left" rowspan="1" colspan="1">&lt;0.001</td>
                          <td align="left" rowspan="1" colspan="1"/>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">Systolic blood pressure, mm Hg</td>
                          <td align="left" rowspan="1" colspan="1">1</td>
                          <td align="left" rowspan="1" colspan="1">135±18 (2925)</td>
                          <td align="left" rowspan="1" colspan="1">132±17 (613)</td>
                          <td align="left" rowspan="1" colspan="1">131±17 (476)</td>
                          <td align="left" rowspan="1" colspan="1">131±18 (302)</td>
                          <td align="left" rowspan="1" colspan="1">&lt;0.001</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1"/>
                          <td align="left" rowspan="1" colspan="1">2</td>
                          <td align="left" rowspan="1" colspan="1">138±18 (1601)</td>
                          <td align="left" rowspan="1" colspan="1">136±18 (1658)</td>
                          <td align="left" rowspan="1" colspan="1">132±18 (975)</td>
                          <td align="left" rowspan="1" colspan="1">130±18 (273)</td>
                          <td align="left" rowspan="1" colspan="1">&lt;0.001</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1"/>
                          <td align="left" rowspan="1" colspan="1">3</td>
                          <td align="left" rowspan="1" colspan="1">139±17 (397)</td>
                          <td align="left" rowspan="1" colspan="1">138±18 (1037)</td>
                          <td align="left" rowspan="1" colspan="1">135±18 (1920)</td>
                          <td align="left" rowspan="1" colspan="1">131±19 (1042)</td>
                          <td align="left" rowspan="1" colspan="1">&lt;0.001</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1"/>
                          <td align="left" rowspan="1" colspan="1">4</td>
                          <td align="left" rowspan="1" colspan="1">142±18 (97)</td>
                          <td align="left" rowspan="1" colspan="1">140±20 (283)</td>
                          <td align="left" rowspan="1" colspan="1">138±19 (1061)</td>
                          <td align="left" rowspan="1" colspan="1">134±19 (2968)</td>
                          <td align="left" rowspan="1" colspan="1">&lt;0.001</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1"><italic>P</italic> value</td>
                          <td align="left" rowspan="1" colspan="1"/>
                          <td align="left" rowspan="1" colspan="1">&lt;0.001</td>
                          <td align="left" rowspan="1" colspan="1">&lt;0.001</td>
                          <td align="left" rowspan="1" colspan="1">&lt;0.001</td>
                          <td align="left" rowspan="1" colspan="1">&lt;0.001</td>
                          <td align="left" rowspan="1" colspan="1"/>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">C‐reactive protein, mg/L</td>
                          <td align="left" rowspan="1" colspan="1">1</td>
                          <td align="left" rowspan="1" colspan="1">1.8 (0.8–3.8) (2897)</td>
                          <td align="left" rowspan="1" colspan="1">1.1 (0.5–2.4) (595)</td>
                          <td align="left" rowspan="1" colspan="1">0.9 (0.4–1.9) (451)</td>
                          <td align="left" rowspan="1" colspan="1">0.7 (0.3–1.4) (276)</td>
                          <td align="left" rowspan="1" colspan="1">&lt;0.001</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1"/>
                          <td align="left" rowspan="1" colspan="1">2</td>
                          <td align="left" rowspan="1" colspan="1">2.1 (1.1–4.1) (1587)</td>
                          <td align="left" rowspan="1" colspan="1">1.5 (0.8–3.2) (1635)</td>
                          <td align="left" rowspan="1" colspan="1">1.2 (0.6–2.6) (970)</td>
                          <td align="left" rowspan="1" colspan="1">1.0 (0.5–2.3) (265)</td>
                          <td align="left" rowspan="1" colspan="1">&lt;0.001</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1"/>
                          <td align="left" rowspan="1" colspan="1">3</td>
                          <td align="left" rowspan="1" colspan="1">2.4 (1.3–4.2) (390)</td>
                          <td align="left" rowspan="1" colspan="1">1.9 (1.0–3.7) (1024)</td>
                          <td align="left" rowspan="1" colspan="1">1.5 (0.8–3.2) (1899)</td>
                          <td align="left" rowspan="1" colspan="1">1.0 (0.5–2.0) (1024)</td>
                          <td align="left" rowspan="1" colspan="1">&lt;0.001</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1"/>
                          <td align="left" rowspan="1" colspan="1">4</td>
                          <td align="left" rowspan="1" colspan="1">3.2 (1.6–5.7) (96)</td>
                          <td align="left" rowspan="1" colspan="1">2.2 (1.2–4.9) (280)</td>
                          <td align="left" rowspan="1" colspan="1">2.0 (1.0–4.0) (1050)</td>
                          <td align="left" rowspan="1" colspan="1">1.4 (0.7–2.9) (2931)</td>
                          <td align="left" rowspan="1" colspan="1">&lt;0.001</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1"><italic>P</italic> value</td>
                          <td align="left" rowspan="1" colspan="1"/>
                          <td align="left" rowspan="1" colspan="1">&lt;0.001</td>
                          <td align="left" rowspan="1" colspan="1">&lt;0.001</td>
                          <td align="left" rowspan="1" colspan="1">&lt;0.001</td>
                          <td align="left" rowspan="1" colspan="1">&lt;0.001</td>
                          <td align="left" rowspan="1" colspan="1"/>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">Metabolic syndrome</td>
                          <td align="left" rowspan="1" colspan="1">1</td>
                          <td align="left" rowspan="1" colspan="1">84.0 (2464/2932)</td>
                          <td align="left" rowspan="1" colspan="1">58.9 (362/615)</td>
                          <td align="left" rowspan="1" colspan="1">35.9 (171/476)</td>
                          <td align="left" rowspan="1" colspan="1">26.8 (81/302)</td>
                          <td align="left" rowspan="1" colspan="1">&lt;0.001</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1"/>
                          <td align="left" rowspan="1" colspan="1">2</td>
                          <td align="left" rowspan="1" colspan="1">82.2 (1319/1605)</td>
                          <td align="left" rowspan="1" colspan="1">77.5 (1285/1658)</td>
                          <td align="left" rowspan="1" colspan="1">77.9 (762/978)</td>
                          <td align="left" rowspan="1" colspan="1">53.1 (145/273)</td>
                          <td align="left" rowspan="1" colspan="1">&lt;0.001</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1"/>
                          <td align="left" rowspan="1" colspan="1">3</td>
                          <td align="left" rowspan="1" colspan="1">78.6 (312/397)</td>
                          <td align="left" rowspan="1" colspan="1">68.3 (710/1039)</td>
                          <td align="left" rowspan="1" colspan="1">66.1 (1271/1924)</td>
                          <td align="left" rowspan="1" colspan="1">72.2 (753/1043)</td>
                          <td align="left" rowspan="1" colspan="1">0.54</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1"/>
                          <td align="left" rowspan="1" colspan="1">4</td>
                          <td align="left" rowspan="1" colspan="1">85.6 (83/97)</td>
                          <td align="left" rowspan="1" colspan="1">61.5 (174/283)</td>
                          <td align="left" rowspan="1" colspan="1">56.1 (598/1066)</td>
                          <td align="left" rowspan="1" colspan="1">53.1 (1580/2973)</td>
                          <td align="left" rowspan="1" colspan="1">&lt;0.001</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1"><italic>P</italic> value</td>
                          <td align="left" rowspan="1" colspan="1"/>
                          <td align="left" rowspan="1" colspan="1">0.02</td>
                          <td align="left" rowspan="1" colspan="1">0.97</td>
                          <td align="left" rowspan="1" colspan="1">0.30</td>
                          <td align="left" rowspan="1" colspan="1">0.07</td>
                          <td align="left" rowspan="1" colspan="1"/>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">Alcohol intake, g/d</td>
                          <td align="left" rowspan="1" colspan="1">1</td>
                          <td align="left" rowspan="1" colspan="1">6.9±10.7 (2830)</td>
                          <td align="left" rowspan="1" colspan="1">7.4 10.4 (539)</td>
                          <td align="left" rowspan="1" colspan="1">7.3±11.4 (464)</td>
                          <td align="left" rowspan="1" colspan="1">8.5±11.4 (297)</td>
                          <td align="left" rowspan="1" colspan="1">0.01</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1"/>
                          <td align="left" rowspan="1" colspan="1">2</td>
                          <td align="left" rowspan="1" colspan="1">8.3±12.1 (1554)</td>
                          <td align="left" rowspan="1" colspan="1">8.5±13.0 (1616)</td>
                          <td align="left" rowspan="1" colspan="1">9.3±12.5 (947)</td>
                          <td align="left" rowspan="1" colspan="1">9.4±12.9 (268)</td>
                          <td align="left" rowspan="1" colspan="1">0.01</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1"/>
                          <td align="left" rowspan="1" colspan="1">3</td>
                          <td align="left" rowspan="1" colspan="1">7.5±11.1 (385)</td>
                          <td align="left" rowspan="1" colspan="1">8.6±13.9 (1007)</td>
                          <td align="left" rowspan="1" colspan="1">8.8±13.6 (1874)</td>
                          <td align="left" rowspan="1" colspan="1">9.5±13.8 (1009)</td>
                          <td align="left" rowspan="1" colspan="1">0.002</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1"/>
                          <td align="left" rowspan="1" colspan="1">4</td>
                          <td align="left" rowspan="1" colspan="1">10±14.7 (90)</td>
                          <td align="left" rowspan="1" colspan="1">8.2±12.9 (276)</td>
                          <td align="left" rowspan="1" colspan="1">8.8±13.3 (1036)</td>
                          <td align="left" rowspan="1" colspan="1">9.8±13.6 (2876)</td>
                          <td align="left" rowspan="1" colspan="1">&lt;0.001</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1"><italic>P</italic> value</td>
                          <td align="left" rowspan="1" colspan="1"/>
                          <td align="left" rowspan="1" colspan="1">0.003</td>
                          <td align="left" rowspan="1" colspan="1">0.36</td>
                          <td align="left" rowspan="1" colspan="1">0.59</td>
                          <td align="left" rowspan="1" colspan="1">0.10</td>
                          <td align="left" rowspan="1" colspan="1"/>
                        </tr>
                      </tbody>
                    </table>
                    <table-wrap-foot>
                      <fn id="jah32453-note-0008">
                        <p>For continuous variables, data are shown as mean±SD or in case of skewed distribution, as median (interquartile range). In each cell, the number between parentheses represents the total number of observations on which the summary estimate was based. For categorical variables, data are presented as percentage, and between parentheses number and total. <italic>P</italic> value is for Jonckheere Terpstra trend test across categories. ApoA‐I indicates apolipoprotein A‐I; EPIC, European Prospective Investigation into Cancer; HDL‐C, high‐density lipoprotein cholesterol.</p>
                      </fn>
                    </table-wrap-foot>
                  </table-wrap>
                </sec>
              </sec>
              <sec id="jah32453-sec-0020">
                <title>Validation in the ARIC and WHS Study</title>
                <sec id="jah32453-sec-0021">
                  <title>Atherosclerosis Risk in Communities (ARIC) Study</title>
                  <p>A full data set was available for 15 494 individuals of the ARIC study. During follow‐up, 2993 (19.3%) subjects experienced a CHD event. Baseline characteristics by quartiles of HDL‐C and apoA‐I are shown in Tables <xref rid="jah32453-sup-0001" ref-type="supplementary-material">S1</xref> and <xref rid="jah32453-sup-0001" ref-type="supplementary-material">S2</xref>.</p>
                  <p>Risk of CHD was strongly and inversely associated with HDL‐C and apoA‐I quartiles in unadjusted and fully adjusted regression analyses (Tables <xref rid="jah32453-sup-0001" ref-type="supplementary-material">S3</xref> and <xref rid="jah32453-sup-0001" ref-type="supplementary-material">S4</xref>). In a 4×4 analysis by HDL‐C and apoA‐I quartiles, a small majority (53%, n=8260) was classified in corresponding HDL‐C and apoA‐I quartiles, whereas 7234 subjects (47%) were not. Within fixed apoA‐I quartiles, HDL‐C levels were associated with a lower rate of CHD events (Table <xref rid="jah32453-sup-0001" ref-type="supplementary-material">S5</xref>). However, apoA‐I levels were not consistently associated with CHD events within fixed HDL‐C quartiles, which is in line with the observations in EPIC‐Norfolk. Finally, the distribution of risk factors across HDL‐C and apoA‐I quartiles is presented in Table <xref rid="jah32453-sup-0001" ref-type="supplementary-material">S6</xref>. There were significant trends across the majority of the HDL‐C and apoA‐I quartiles for percentage males, body mass index, non‐HDL‐C, triglycerides, apoB, systolic blood pressure, and prevalence of metabolic syndrome. The characteristics of the individuals at the extremes of the distribution were fundamentally different; the group defined by high HDL‐C and low apoA‐I levels consisted of relatively healthy subjects compared with the group defined by low HDL‐C and high apoA‐I levels, where an enrichment of traditional risk factors was observed, similar to the associations observed in EPIC‐Norfolk.</p>
                </sec>
                <sec id="jah32453-sec-0022">
                  <title>The Women's Health Study</title>
                  <p>Of the total 27 552 female participants in the WHS, 1071 (3.9%) experienced a CHD event. Because of the lower CHD event rate, analyses were performed for tertiles of HDL‐C and apoA‐I. Again, both HDL‐C and apoA‐I levels were strongly and inversely associated with CHD risk in unadjusted and fully adjusted models (Tables <xref rid="jah32453-sup-0001" ref-type="supplementary-material">S7</xref> and <xref rid="jah32453-sup-0001" ref-type="supplementary-material">S8</xref>). In a 3×3 analysis by apoA‐I and HDL‐C tertiles, 18 101 (67%) were classified in corresponding tertiles, in contrast to 9052 (33%) participants who were in different tertiles for HDL‐C and apoA‐I (Table <xref rid="jah32453-sup-0001" ref-type="supplementary-material">S9</xref>). Within fixed apoA‐I tertiles, higher HDL‐C levels were consistently associated with lower CHD risk. However, no consistent association for apoA‐I and CHD risk was observed, within fixed HDL‐C tertiles. In fact, for apoA‐I levels there was a trend towards higher CHD risk, within fixed HDL‐C tertiles, which was statistically significant for the second HDL‐C tertile (<italic>P</italic>=0.002).</p>
                </sec>
              </sec>
            </sec>
            <sec id="jah32453-sec-0023">
              <title>Discussion</title>
              <p>We present data on the associations between plasma levels of HDL‐C and apoA‐I, cardiovascular risk factors and risk of CHD in the EPIC‐Norfolk cohort. As expected, both HDL‐C and apoA‐I were strongly and inversely associated with the risk of future CHD. It is noteworthy, however, that these associations were not interchangeable. We found that within each apoA‐I quartile, higher plasma HDL‐C levels were consistently associated with lower CHD risk. There was, however, no consistent reverse association between apoA‐I levels and CHD risk within each HDL‐C quartile, and in the EPIC‐Norfolk study we even observed a trend towards increased risk in some apoA‐I quartiles. This was supported by the unexpected observation that CHD risk factors were positively associated with apoA‐I levels within all HDL‐C quartiles. In contrast, HDL‐C was inversely associated with CHD risk factors within apoA‐I quartiles. These findings were externally validated in both the ARIC and WHS studies, and the fact that the observations were consistent in these prospective studies suggests a biologically relevant association.</p>
              <p>A number of studies have shown that HDL‐C and apoA‐I levels are inversely associated with CHD risk. In most subjects, HDL‐C and apoA‐I levels are closely correlated, and in the EPIC‐Norfolk study HDL‐C and apoA‐I quartiles were concordant in more than half of the participants. This concordance might explain why HDL‐C and apoA‐I have shown similar association with risk of cardiovascular events in previous studies.<xref rid="jah32453-bib-0005" ref-type="ref">5</xref>
</p>
              <p>Several studies have addressed the question of the relative contribution and/or superiority of HDL‐C and apoA‐I levels to CHD risk previously, by comparing their effects in multivariable adjusted regression models. In Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (INTERHEART), the association between apoA‐I and CHD risk was stronger than for HDL‐C.<xref rid="jah32453-bib-0024" ref-type="ref">24</xref> However, INTERHEART was not a prospective study and did not assess hazard ratios for CHD risk by quartiles of apoA‐I and HDL‐C. The ERFC (Emerging Risk Factors Collaboration) reported that when apoA‐I was added to risk scores containing HDL‐C, this led to a slight improvement of cardiovascular disease risk assessment; however, the clinical relevance was questioned.<xref rid="jah32453-bib-0013" ref-type="ref">13</xref> In fact, we reported in a previous article, based on 2349 study participants in a nested case–control set within the EPIC‐Norfolk cohort, that the negative association between HDL‐C levels and risk of major coronary events was lost upon adjustment for apoA‐I and apoB, whereas upon adjustment for HDL‐C and apoB the association between apoA‐I and risk of major coronary events was retained.<xref rid="jah32453-bib-0025" ref-type="ref">25</xref>
</p>
              <p>The strong and complex relationships between HDL‐C versus apoA‐I and other cardiometabolic risk factors make it very difficult to disentangle associations with risk of cardiovascular events, especially when using complex multivariable adjusted regression models. Our current rigorous approach using 4×4 tables to assess these independent associations provides better insight, but can only be performed in very large data sets from prospective cohorts, such as the EPIC‐Norfolk, ARIC, and WHS data sets.</p>
              <p>In our study, there was no significant association between apoA‐I quartiles with the exception of some quartiles where CHD risk was in fact positive rather than inverse. This positive association between CHD risk and apoA‐I quartiles has not been reported before. Our results indicate that the predictive value of apoA‐I, if anything, does not outperform the predictive value of HDL‐C.</p>
              <p>The prevalence of CHD risk factors across quartiles of HDL‐C and apoA‐I confirms our observations. First, we noticed a robust enrichment of risk factors in participants within the lowest HDL‐C but highest apoA‐I quartile. In other words, subjects with a combined phenotype of low HDL‐C and high apoA‐I levels are characterized by high levels of triglycerides, apoB, and CRP, and high prevalence of hypertension and metabolic syndrome. Second, we observed that whereas HDL‐C quartiles are inversely correlated with all analyzed cardiovascular risk factors, people with the highest apoA‐I levels within each HDL‐C quartile are characterized by a high prevalence of risk factors; age, body mass index, triglycerides, systolic blood pressure, CRP, prevalence of metabolic syndrome, and percentage males were consistently higher in participants in the top apoA‐I quartile compared with those in the lowest quartile, irrespective of the HDL‐C quartile. This phenomenon, which we found to be consistent among 3 large prospective studies and within all HDL‐C quartiles, has so far not been described in the literature. This unexpected association between established cardiovascular risk factors and apoA‐I was possibly not acknowledged to date because it was masked by the very close relationship between apoA‐I and HDL‐C.</p>
              <p>A possible mechanism could be related to the increased rate of metabolic syndrome observed in the high apoA‐I quartiles, which has been shown to coincide with high plasma levels of endogenous corticosteroids such as glucocorticoids<xref rid="jah32453-bib-0026" ref-type="ref">26</xref>, <xref rid="jah32453-bib-0027" ref-type="ref">27</xref> and androgens,<xref rid="jah32453-bib-0028" ref-type="ref">28</xref> which in turn leads to higher levels of apoB and apoA‐I.<xref rid="jah32453-bib-0029" ref-type="ref">29</xref> This might imply that individuals in the high HDL‐C/high apoA‐I quartiles are characterized by overproduction of not only apoB but also apoA‐I.</p>
              <sec id="jah32453-sec-0024">
                <title>Limitations</title>
                <p>Several aspects of this study merit attention when interpreting the results. First, although HDL‐C and apoA‐I measurements were available in a large set of study participants, these measurements do not inform us about the apolipoprotein content of HDL particles and the intraindividual range of apoA‐I molecules per particle.<xref rid="jah32453-bib-0030" ref-type="ref">30</xref> Second, samples in EPIC‐Norfolk were not drawn in a fasting state, although the majority of samples in WHS were fasting. The fact that HDL‐C and apoA‐I are not strongly affected by a meal does not exclude the possibility of spurious associations. Third, CHD events in EPIC Norfolk were based on ICD coding for hospitalizations and death certificates, and not adjudicated specifically for the purpose of this study, although events were adjudicated by medical record review for WHS and ARIC. The small numbers of participants and CHD events in the extremes of the HDL‐C and apoA‐I distributions warrant caution when interpreting the hazard ratios for these groups. Lastly, we did not have data on diabetes mellitus duration available and only HbA1C levels were available for 50% of the cohort and we are therefore not fully informed on diabetes mellitus severity or prediabetic conditions. We did adjust for diabetes mellitus status, which was available for all study participants, but cannot rule out that the confounding effect of glucose metabolism might be underestimated in our study.</p>
                <p>In conclusion, we show that both HDL‐C and apoA‐I are inversely correlated with CHD risk. Our findings demonstrate that apoA‐I levels do not offer predictive information over and above HDL‐C. In fact, within fixed HDL‐C quartiles, higher apoA‐I levels were associated with a higher prevalence of cardiovascular risk factors. This finding is new and unexpected and was found consistently among the 3 cohorts that were studied. This could be a relevant finding in light of the current development of apoA‐I increasing strategies.</p>
              </sec>
            </sec>
            <sec id="jah32453-sec-0026">
              <title>Sources of Funding</title>
              <p>Prof Kastelein is a recipient of The lifetime Achievement Award of The Dutch Heart Foundation (2011, the Hague, the Netherlands). Dr Hovingh is a recipient of a Vidi grant (project number 016.156.445) from the Netherlands Organisation for Scientific Research (NWO) and the European Union (Transcard FP7‐603091‐2). The apolipoprotein measurements in the full cohort were supported by a grant from the Medical Research Council to the MRC Epidemiology Unit, Cambridge, UK (MRC G0701863). Dr Mora was funded by grants HL117861, HL117861‐S1, and S2, and by the Molino Family Trust. The Women's Health Study was supported by grants HL043851, HL 080467, HL 099355, CA 047988, and I&lt;1 CA 182913 from the National Heart, Lung, and Blood Institute and the National Cancer Institute, National Institutes of Health. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.</p>
            </sec>
            <sec id="jah32453-sec-0027">
              <title>Disclosures</title>
              <p>Dr Mora has received research grant support from Atherotech Diagnostics, and National Heart, Lung, and Blood Institute (NHLBI), and served as a consultant for Pfizer, Quest Diagnostics, Genzyme, and Cerenis Therapeutics. Dr Ridker has received research grant support from AstraZeneca, Novartis, Amgen, Pfizer, Kowa, and NHLBI and has served as a consultant to Genzyme, Jannsen, Aegerion, ISIS, Vascular Biogenics, Boeringer, and Merck. Dr Ridker is listed as a co‐inventor on patents held by the Brigham and Women's Hospital that relate to the use of inflammatory biomarkers in cardiovascular disease that have been licensed to AstraZeneca and Siemens.</p>
            </sec>
            <sec sec-type="supplementary-material">
              <title>Supporting information</title>
              <supplementary-material content-type="local-data" id="jah32453-sup-0001">
                <caption>
                  <p><bold>Table S1.</bold> Baseline Characteristics by HDL Cholesterol Quartiles in the ARIC Study</p>
                  <p><bold>Table S2.</bold> Baseline Characteristics by Apolipoprotein A‐I Quartiles in the ARIC Study</p>
                  <p><bold>Table S3.</bold> Risk of Coronary Heart Disease Events by HDL Cholesterol Quartiles in the ARIC Study</p>
                  <p><bold>Table S4.</bold> Risk of Coronary Heart Disease Events by Apolipoprotein A‐I Quartiles in the ARIC Study</p>
                  <p><bold>Table S5.</bold> Risk of Coronary Heart Disease Events by HDL Cholesterol and Apolipoprotein A‐I Quartiles in the ARIC Study</p>
                  <p><bold>Table S6.</bold> Baseline Characteristics by HDL‐C and apoA‐I Quartiles in the ARIC Study</p>
                  <p><bold>Table S7.</bold> Risk of Coronary Heart Disease Events by HDL Cholesterol Tertiles in WHS</p>
                  <p><bold>Table S8.</bold> Risk of Coronary Heart Disease Events by Apolipoprotein A‐I Tertiles in WHS</p>
                  <p><bold>Table S9.</bold> Risk of Coronary Heart Disease Events by HDL Cholesterol and Apolipoprotein A‐I Tertiles in WHS</p>
                </caption>
                <media xlink:href="JAH3-6-e006636-s001.pdf">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
            </sec>
          </body>
          <back>
            <ack id="jah32453-sec-0025">
              <title>Acknowledgments</title>
              <p>The authors would like to thank the participants, general practitioners, and staff of the EPIC‐Norfolk cohort study. We are grateful to the laboratory teams of the Medical Research Council Epidemiology Unit for the coordination of the cohort‐wide biochemistry measurements. The authors thank the staff and participants of the ARIC and WHS studies for their important contributions.</p>
            </ack>
            <ref-list content-type="cited-references" id="jah32453-bibl-0001">
              <title>References</title>
              <ref id="jah32453-bib-0001">
                <label>1</label>
                <mixed-citation publication-type="journal" id="jah32453-cit-0001"><string-name><surname>Voight</surname><given-names>BF</given-names></string-name>, <string-name><surname>Peloso</surname><given-names>GM</given-names></string-name>, <string-name><surname>Orho‐Melander</surname><given-names>M</given-names></string-name>, <string-name><surname>Frikke‐Schmidt</surname><given-names>R</given-names></string-name>, <string-name><surname>Barbalic</surname><given-names>M</given-names></string-name>, <string-name><surname>Jensen</surname><given-names>MK</given-names></string-name>, <string-name><surname>Hindy</surname><given-names>G</given-names></string-name>, <string-name><surname>Hólm</surname><given-names>H</given-names></string-name>, <string-name><surname>Ding</surname><given-names>EL</given-names></string-name>, <string-name><surname>Johnson</surname><given-names>T</given-names></string-name>, <string-name><surname>Schunkert</surname><given-names>H</given-names></string-name>, <string-name><surname>Samani</surname><given-names>NJ</given-names></string-name>, <string-name><surname>Clarke</surname><given-names>R</given-names></string-name>, <string-name><surname>Hopewell</surname><given-names>JC</given-names></string-name>, <string-name><surname>Thompson</surname><given-names>JF</given-names></string-name>, <string-name><surname>Li</surname><given-names>M</given-names></string-name>, <string-name><surname>Thorleifsson</surname><given-names>G</given-names></string-name>, <string-name><surname>Newton‐Cheh</surname><given-names>C</given-names></string-name>, <string-name><surname>Musunuru</surname><given-names>K</given-names></string-name>, <string-name><surname>Pirruccello</surname><given-names>JP</given-names></string-name>, <string-name><surname>Saleheen</surname><given-names>D</given-names></string-name>, <string-name><surname>Chen</surname><given-names>L</given-names></string-name>, <string-name><surname>Stewart</surname><given-names>AF</given-names></string-name>, <string-name><surname>Schillert</surname><given-names>A</given-names></string-name>, <string-name><surname>Thorsteinsdottir</surname><given-names>U</given-names></string-name>, <string-name><surname>Thorgeirsson</surname><given-names>G</given-names></string-name>, <string-name><surname>Anand</surname><given-names>S</given-names></string-name>, <string-name><surname>Engert</surname><given-names>JC</given-names></string-name>, <string-name><surname>Morgan</surname><given-names>T</given-names></string-name>, <string-name><surname>Spertus</surname><given-names>J</given-names></string-name>, <string-name><surname>Stoll</surname><given-names>M</given-names></string-name>, <string-name><surname>Berger</surname><given-names>K</given-names></string-name>, <string-name><surname>Martinelli</surname><given-names>N</given-names></string-name>, <string-name><surname>Girelli</surname><given-names>D</given-names></string-name>, <string-name><surname>McKeown</surname><given-names>PP</given-names></string-name>, <string-name><surname>Patterson</surname><given-names>CC</given-names></string-name>, <string-name><surname>Epstein</surname><given-names>SE</given-names></string-name>, <string-name><surname>Devaney</surname><given-names>J</given-names></string-name>, <string-name><surname>Burnett</surname><given-names>M‐S</given-names></string-name>, <string-name><surname>Mooser</surname><given-names>V</given-names></string-name>, <string-name><surname>Ripatti</surname><given-names>S</given-names></string-name>, <string-name><surname>Surakka</surname><given-names>I</given-names></string-name>, <string-name><surname>Nieminen</surname><given-names>MS</given-names></string-name>, <string-name><surname>Sinisalo</surname><given-names>J</given-names></string-name>, <string-name><surname>Lokki</surname><given-names>M‐L</given-names></string-name>, <string-name><surname>Perola</surname><given-names>M</given-names></string-name>, <string-name><surname>Havulinna</surname><given-names>A</given-names></string-name>, <string-name><surname>de Faire</surname><given-names>U</given-names></string-name>, <string-name><surname>Gigante</surname><given-names>B</given-names></string-name>, <string-name><surname>Ingelsson</surname><given-names>E</given-names></string-name>, <string-name><surname>Zeller</surname><given-names>T</given-names></string-name>, <string-name><surname>Wild</surname><given-names>P</given-names></string-name>, <string-name><surname>de Bakker</surname><given-names>PIW</given-names></string-name>, <string-name><surname>Klungel</surname><given-names>OH</given-names></string-name>, <string-name><surname>Maitland‐van der Zee</surname><given-names>A‐H</given-names></string-name>, <string-name><surname>Peters</surname><given-names>BJM</given-names></string-name>, <string-name><surname>de Boer</surname><given-names>A</given-names></string-name>, <string-name><surname>Grobbee</surname><given-names>DE</given-names></string-name>, <string-name><surname>Kamphuisen</surname><given-names>PW</given-names></string-name>, <string-name><surname>Deneer</surname><given-names>VHM</given-names></string-name>, <string-name><surname>Elbers</surname><given-names>CC</given-names></string-name>, <string-name><surname>Onland‐Moret</surname><given-names>NC</given-names></string-name>, <string-name><surname>Hofker</surname><given-names>MH</given-names></string-name>, <string-name><surname>Wijmenga</surname><given-names>C</given-names></string-name>, <string-name><surname>Verschuren</surname><given-names>WM</given-names></string-name>, <string-name><surname>Boer</surname><given-names>JM</given-names></string-name>, <string-name><surname>van der Schouw</surname><given-names>YT</given-names></string-name>, <string-name><surname>Rasheed</surname><given-names>A</given-names></string-name>, <string-name><surname>Frossard</surname><given-names>P</given-names></string-name>, <string-name><surname>Demissie</surname><given-names>S</given-names></string-name>, <string-name><surname>Willer</surname><given-names>C</given-names></string-name>, <string-name><surname>Do</surname><given-names>R</given-names></string-name>, <string-name><surname>Ordovas</surname><given-names>JM</given-names></string-name>, <string-name><surname>Abecasis</surname><given-names>GR</given-names></string-name>, <string-name><surname>Boehnke</surname><given-names>M</given-names></string-name>, <string-name><surname>Mohlke</surname><given-names>KL</given-names></string-name>, <string-name><surname>Daly</surname><given-names>MJ</given-names></string-name>, <string-name><surname>Guiducci</surname><given-names>C</given-names></string-name>, <string-name><surname>Burtt</surname><given-names>NP</given-names></string-name>, <string-name><surname>Surti</surname><given-names>A</given-names></string-name>, <string-name><surname>Gonzalez</surname><given-names>E</given-names></string-name>, <string-name><surname>Purcell</surname><given-names>S</given-names></string-name>, <string-name><surname>Gabriel</surname><given-names>S</given-names></string-name>, <string-name><surname>Marrugat</surname><given-names>J</given-names></string-name>, <string-name><surname>Peden</surname><given-names>J</given-names></string-name>, <string-name><surname>Erdmann</surname><given-names>J</given-names></string-name>, <string-name><surname>Diemert</surname><given-names>P</given-names></string-name>, <string-name><surname>Willenborg</surname><given-names>C</given-names></string-name>, <string-name><surname>König</surname><given-names>IR</given-names></string-name>, <string-name><surname>Fischer</surname><given-names>M</given-names></string-name>, <string-name><surname>Hengstenberg</surname><given-names>C</given-names></string-name>, <string-name><surname>Ziegler</surname><given-names>A</given-names></string-name>, <string-name><surname>Buysschaert</surname><given-names>I</given-names></string-name>, <string-name><surname>Lambrechts</surname><given-names>D</given-names></string-name>, <string-name><surname>Van de Werf</surname><given-names>F</given-names></string-name>, <string-name><surname>Fox</surname><given-names>KA</given-names></string-name>, <string-name><surname>El Mokhtari</surname><given-names>NE</given-names></string-name>, <string-name><surname>Rubin</surname><given-names>D</given-names></string-name>, <string-name><surname>Schrezenmeir</surname><given-names>J</given-names></string-name>, <string-name><surname>Schreiber</surname><given-names>S</given-names></string-name>, <string-name><surname>Schäfer</surname><given-names>A</given-names></string-name>, <string-name><surname>Danesh</surname><given-names>J</given-names></string-name>, <string-name><surname>Blankenberg</surname><given-names>S</given-names></string-name>, <string-name><surname>Roberts</surname><given-names>R</given-names></string-name>, <string-name><surname>McPherson</surname><given-names>R</given-names></string-name>, <string-name><surname>Watkins</surname><given-names>H</given-names></string-name>, <string-name><surname>Hall</surname><given-names>AS</given-names></string-name>, <string-name><surname>Overvad</surname><given-names>K</given-names></string-name>, <string-name><surname>Rimm</surname><given-names>E</given-names></string-name>, <string-name><surname>Boerwinkle</surname><given-names>E</given-names></string-name>, <string-name><surname>Tybjaerg‐Hansen</surname><given-names>A</given-names></string-name>, <string-name><surname>Cupples</surname><given-names>LA</given-names></string-name>, <string-name><surname>Reilly</surname><given-names>MP</given-names></string-name>, <string-name><surname>Melander</surname><given-names>O</given-names></string-name>, <string-name><surname>Mannucci</surname><given-names>PM</given-names></string-name>, <string-name><surname>Ardissino</surname><given-names>D</given-names></string-name>, <string-name><surname>Siscovick</surname><given-names>D</given-names></string-name>, <string-name><surname>Elosua</surname><given-names>R</given-names></string-name>, <string-name><surname>Stefansson</surname><given-names>K</given-names></string-name>, <string-name><surname>O'Donnell</surname><given-names>CJ</given-names></string-name>, <string-name><surname>Salomaa</surname><given-names>V</given-names></string-name>, <string-name><surname>Rader</surname><given-names>DJ</given-names></string-name>, <string-name><surname>Peltonen</surname><given-names>L</given-names></string-name>, <string-name><surname>Schwartz</surname><given-names>SM</given-names></string-name>, <string-name><surname>Altshuler</surname><given-names>D</given-names></string-name>, <string-name><surname>Kathiresan</surname><given-names>S</given-names></string-name>. <article-title>Plasma HDL cholesterol and risk of myocardial infarction: a Mendelian randomisation study</article-title>. <source>Lancet</source>. <year>2012</year>;<volume>380</volume>:<fpage>572</fpage>–<lpage>580</lpage>.<pub-id pub-id-type="pmid">22607825</pub-id></mixed-citation>
              </ref>
              <ref id="jah32453-bib-0002">
                <label>2</label>
                <mixed-citation publication-type="journal" id="jah32453-cit-0002"><string-name><surname>Boden</surname><given-names>WE</given-names></string-name>, <string-name><surname>Probstfield</surname><given-names>JL</given-names></string-name>, <string-name><surname>Anderson</surname><given-names>T</given-names></string-name>, <string-name><surname>Chaitman</surname><given-names>BR</given-names></string-name>, <string-name><surname>Desvignes‐Nickens</surname><given-names>P</given-names></string-name>, <string-name><surname>Koprowicz</surname><given-names>K</given-names></string-name>, <string-name><surname>McBride</surname><given-names>R</given-names></string-name>, <string-name><surname>Teo</surname><given-names>K</given-names></string-name>, <string-name><surname>Weintraub</surname><given-names>W</given-names></string-name>. <article-title>Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy</article-title>. <source>N Engl J Med</source>. <year>2011</year>;<volume>365</volume>:<fpage>2255</fpage>–<lpage>2267</lpage>.<pub-id pub-id-type="pmid">22085343</pub-id></mixed-citation>
              </ref>
              <ref id="jah32453-bib-0003">
                <label>3</label>
                <mixed-citation publication-type="journal" id="jah32453-cit-0003"><string-name><surname>Schwartz</surname><given-names>GG</given-names></string-name>, <string-name><surname>Olsson</surname><given-names>AG</given-names></string-name>, <string-name><surname>Abt</surname><given-names>M</given-names></string-name>, <string-name><surname>Ballantyne</surname><given-names>CM</given-names></string-name>, <string-name><surname>Barter</surname><given-names>PJ</given-names></string-name>, <string-name><surname>Brumm</surname><given-names>J</given-names></string-name>, <string-name><surname>Chaitman</surname><given-names>BR</given-names></string-name>, <string-name><surname>Holme</surname><given-names>IM</given-names></string-name>, <string-name><surname>Kallend</surname><given-names>D</given-names></string-name>, <string-name><surname>Leiter</surname><given-names>LA</given-names></string-name>, <string-name><surname>Leitersdorf</surname><given-names>E</given-names></string-name>, <string-name><surname>McMurray</surname><given-names>JJ</given-names></string-name>, <string-name><surname>Mundl</surname><given-names>H</given-names></string-name>, <string-name><surname>Nicholls</surname><given-names>SJ</given-names></string-name>, <string-name><surname>Shah</surname><given-names>PK</given-names></string-name>, <string-name><surname>Tardif</surname><given-names>J‐C</given-names></string-name>, <string-name><surname>Wright</surname><given-names>RS</given-names></string-name>. <article-title>Effects of dalcetrapib in patients with a recent acute coronary syndrome</article-title>. <source>N Engl J Med</source>. <year>2012</year>;<volume>367</volume>:<fpage>2089</fpage>–<lpage>2099</lpage>.<pub-id pub-id-type="pmid">23126252</pub-id></mixed-citation>
              </ref>
              <ref id="jah32453-bib-0004">
                <label>4</label>
                <mixed-citation publication-type="journal" id="jah32453-cit-0004"><string-name><surname>Lincoff</surname><given-names>AM</given-names></string-name>, <string-name><surname>Nicholls</surname><given-names>SJ</given-names></string-name>, <string-name><surname>Riesmeyer</surname><given-names>JS</given-names></string-name>, <string-name><surname>Barter</surname><given-names>PJ</given-names></string-name>, <string-name><surname>Brewer</surname><given-names>HB</given-names></string-name>, <string-name><surname>Fox</surname><given-names>KAA</given-names></string-name>, <string-name><surname>Gibson</surname><given-names>CM</given-names></string-name>, <string-name><surname>Granger</surname><given-names>C</given-names></string-name>, <string-name><surname>Menon</surname><given-names>V</given-names></string-name>, <string-name><surname>Montalescot</surname><given-names>G</given-names></string-name>, <string-name><surname>Rader</surname><given-names>D</given-names></string-name>, <string-name><surname>Tall</surname><given-names>AR</given-names></string-name>, <string-name><surname>McErlean</surname><given-names>E</given-names></string-name>, <string-name><surname>Wolski</surname><given-names>K</given-names></string-name>, <string-name><surname>Ruotolo</surname><given-names>G</given-names></string-name>, <string-name><surname>Vangerow</surname><given-names>B</given-names></string-name>, <string-name><surname>Weerakkody</surname><given-names>G</given-names></string-name>, <string-name><surname>Goodman</surname><given-names>SG</given-names></string-name>, <string-name><surname>Conde</surname><given-names>D</given-names></string-name>, <string-name><surname>McGuire</surname><given-names>DK</given-names></string-name>, <string-name><surname>Nicolau</surname><given-names>JC</given-names></string-name>, <string-name><surname>Leiva‐Pons</surname><given-names>JL</given-names></string-name>, <string-name><surname>Pesant</surname><given-names>Y</given-names></string-name>, <string-name><surname>Li</surname><given-names>W</given-names></string-name>, <string-name><surname>Kandath</surname><given-names>D</given-names></string-name>, <string-name><surname>Kouz</surname><given-names>S</given-names></string-name>, <string-name><surname>Tahirkheli</surname><given-names>N</given-names></string-name>, <string-name><surname>Mason</surname><given-names>D</given-names></string-name>, <string-name><surname>Nissen</surname><given-names>SE</given-names></string-name>; <collab collab-type="authors">ACCELERATE Investigators</collab>
. <article-title>Evacetrapib and cardiovascular outcomes in high‐risk vascular disease</article-title>. <source>N Engl J Med</source>. <year>2017</year>;<volume>376</volume>:<fpage>1933</fpage>–<lpage>1942</lpage>.<pub-id pub-id-type="pmid">28514624</pub-id></mixed-citation>
              </ref>
              <ref id="jah32453-bib-0005">
                <label>5</label>
                <mixed-citation publication-type="journal" id="jah32453-cit-0005"><collab collab-type="authors">Emerging Risk Factors Collaboration</collab>
, <string-name><surname>Di Angelantonio</surname><given-names>E</given-names></string-name>, <string-name><surname>Sarwar</surname><given-names>N</given-names></string-name>, <string-name><surname>Perry</surname><given-names>P</given-names></string-name>, <string-name><surname>Kaptoge</surname><given-names>S</given-names></string-name>, <string-name><surname>Ray</surname><given-names>KK</given-names></string-name>, <string-name><surname>Thompson</surname><given-names>A</given-names></string-name>, <string-name><surname>Wood</surname><given-names>AM</given-names></string-name>, <string-name><surname>Lewington</surname><given-names>S</given-names></string-name>, <string-name><surname>Sattar</surname><given-names>N</given-names></string-name>, <string-name><surname>Packard</surname><given-names>CJ</given-names></string-name>, <string-name><surname>Collins</surname><given-names>R</given-names></string-name>, <string-name><surname>Thompson</surname><given-names>SG</given-names></string-name>, <string-name><surname>Danesh</surname><given-names>J</given-names></string-name>. <article-title>Major lipids, apolipoproteins, and risk of vascular disease</article-title>. <source>JAMA</source>. <year>2009</year>;<volume>302</volume>:<fpage>1993</fpage>–<lpage>2000</lpage>.<pub-id pub-id-type="pmid">19903920</pub-id></mixed-citation>
              </ref>
              <ref id="jah32453-bib-0006">
                <label>6</label>
                <mixed-citation publication-type="journal" id="jah32453-cit-0006"><string-name><surname>Barter</surname><given-names>PJ</given-names></string-name>, <string-name><surname>Rye</surname><given-names>K‐A</given-names></string-name>. <article-title>The rationale for using apoA‐I as a clinical marker of cardiovascular risk</article-title>. <source>J Intern Med</source>. <year>2006</year>;<volume>259</volume>:<fpage>447</fpage>–<lpage>454</lpage>.<pub-id pub-id-type="pmid">16629850</pub-id></mixed-citation>
              </ref>
              <ref id="jah32453-bib-0007">
                <label>7</label>
                <mixed-citation publication-type="journal" id="jah32453-cit-0007"><string-name><surname>Mineo</surname><given-names>C</given-names></string-name>, <string-name><surname>Shaul</surname><given-names>PW</given-names></string-name>. <article-title>Novel biological functions of high‐density lipoprotein cholesterol</article-title>. <source>Circ Res</source>. <year>2012</year>;<volume>111</volume>:<fpage>1079</fpage>–<lpage>1090</lpage>.<pub-id pub-id-type="pmid">23023510</pub-id></mixed-citation>
              </ref>
              <ref id="jah32453-bib-0008">
                <label>8</label>
                <mixed-citation publication-type="journal" id="jah32453-cit-0008"><string-name><surname>Guo</surname><given-names>Y</given-names></string-name>, <string-name><surname>Fan</surname><given-names>Y</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>J</given-names></string-name>, <string-name><surname>Lomberk</surname><given-names>GA</given-names></string-name>, <string-name><surname>Zhou</surname><given-names>Z</given-names></string-name>, <string-name><surname>Sun</surname><given-names>L</given-names></string-name>, <string-name><surname>Mathison</surname><given-names>AJ</given-names></string-name>, <string-name><surname>Garcia‐Barrio</surname><given-names>MT</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>J</given-names></string-name>, <string-name><surname>Zeng</surname><given-names>L</given-names></string-name>, <string-name><surname>Li</surname><given-names>L</given-names></string-name>, <string-name><surname>Pennathur</surname><given-names>S</given-names></string-name>, <string-name><surname>Willer</surname><given-names>CJ</given-names></string-name>, <string-name><surname>Rader</surname><given-names>DJ</given-names></string-name>, <string-name><surname>Urrutia</surname><given-names>R</given-names></string-name>, <string-name><surname>Chen</surname><given-names>YE</given-names></string-name>. <article-title>Perhexiline activates KLF14 and reduces atherosclerosis by modulating ApoA‐I production</article-title>. <source>J Clin Invest</source>. <year>2015</year>;<volume>125</volume>:<fpage>3819</fpage>–<lpage>3830</lpage>.<pub-id pub-id-type="pmid">26368306</pub-id></mixed-citation>
              </ref>
              <ref id="jah32453-bib-0009">
                <label>9</label>
                <mixed-citation publication-type="journal" id="jah32453-cit-0009"><string-name><surname>Waksman</surname><given-names>R</given-names></string-name>, <string-name><surname>Torguson</surname><given-names>R</given-names></string-name>, <string-name><surname>Kent</surname><given-names>KM</given-names></string-name>, <string-name><surname>Pichard</surname><given-names>AD</given-names></string-name>, <string-name><surname>Suddath</surname><given-names>WO</given-names></string-name>, <string-name><surname>Satler</surname><given-names>LF</given-names></string-name>, <string-name><surname>Martin</surname><given-names>BD</given-names></string-name>, <string-name><surname>Perlman</surname><given-names>TJ</given-names></string-name>, <string-name><surname>Maltais</surname><given-names>J‐AB</given-names></string-name>, <string-name><surname>Weissman</surname><given-names>NJ</given-names></string-name>, <string-name><surname>Fitzgerald</surname><given-names>PJ</given-names></string-name>, <string-name><surname>Brewer</surname><given-names>HB</given-names></string-name>. <article-title>A first‐in‐man, randomized, placebo‐controlled study to evaluate the safety and feasibility of autologous delipidated high‐density lipoprotein plasma infusions in patients with acute coronary syndrome</article-title>. <source>J Am Coll Cardiol</source>. <year>2010</year>;<volume>55</volume>:<fpage>2727</fpage>–<lpage>2735</lpage>.<pub-id pub-id-type="pmid">20538165</pub-id></mixed-citation>
              </ref>
              <ref id="jah32453-bib-0010">
                <label>10</label>
                <mixed-citation publication-type="journal" id="jah32453-cit-0010"><string-name><surname>Tardif</surname><given-names>J‐C</given-names></string-name>, <string-name><surname>Ballantyne</surname><given-names>CM</given-names></string-name>, <string-name><surname>Barter</surname><given-names>P</given-names></string-name>, <string-name><surname>Dasseux</surname><given-names>J‐L</given-names></string-name>, <string-name><surname>Fayad</surname><given-names>ZA</given-names></string-name>, <string-name><surname>Guertin</surname><given-names>M‐C</given-names></string-name>, <string-name><surname>Kastelein</surname><given-names>JJP</given-names></string-name>, <string-name><surname>Keyserling</surname><given-names>C</given-names></string-name>, <string-name><surname>Klepp</surname><given-names>H</given-names></string-name>, <string-name><surname>Koenig</surname><given-names>W</given-names></string-name>, <string-name><surname>L'Allier</surname><given-names>PL</given-names></string-name>, <string-name><surname>Lespérance</surname><given-names>J</given-names></string-name>, <string-name><surname>Lüscher</surname><given-names>TF</given-names></string-name>, <string-name><surname>Paolini</surname><given-names>JF</given-names></string-name>, <string-name><surname>Tawakol</surname><given-names>A</given-names></string-name>, <string-name><surname>Waters</surname><given-names>DD</given-names></string-name>; <collab collab-type="authors">Can HDL Infusions Significantly QUicken Atherosclerosis REgression (CHI‐SQUARE) Investigators</collab>
. <article-title>Effects of the high‐density lipoprotein mimetic agent CER‐001 on coronary atherosclerosis in patients with acute coronary syndromes: a randomized trial</article-title>. <source>Eur Heart J</source>. <year>2014</year>;<volume>35</volume>:<fpage>3277</fpage>–<lpage>3286</lpage>.<pub-id pub-id-type="pmid">24780501</pub-id></mixed-citation>
              </ref>
              <ref id="jah32453-bib-0011">
                <label>11</label>
                <mixed-citation publication-type="journal" id="jah32453-cit-0011"><string-name><surname>Nicholls</surname><given-names>SJ</given-names></string-name>, <string-name><surname>Puri</surname><given-names>R</given-names></string-name>, <string-name><surname>Wolski</surname><given-names>K</given-names></string-name>, <string-name><surname>Ballantyne</surname><given-names>CM</given-names></string-name>, <string-name><surname>Barter</surname><given-names>PJ</given-names></string-name>, <string-name><surname>Brewer</surname><given-names>HB</given-names></string-name>, <string-name><surname>Kastelein</surname><given-names>JJP</given-names></string-name>, <string-name><surname>Hu</surname><given-names>B</given-names></string-name>, <string-name><surname>Uno</surname><given-names>K</given-names></string-name>, <string-name><surname>Kataoka</surname><given-names>Y</given-names></string-name>, <string-name><surname>Herrman</surname><given-names>J‐PR</given-names></string-name>, <string-name><surname>Merkely</surname><given-names>B</given-names></string-name>, <string-name><surname>Borgman</surname><given-names>M</given-names></string-name>, <string-name><surname>Nissen</surname><given-names>SE</given-names></string-name>. <article-title>Effect of the BET protein inhibitor, RVX‐208, on progression of coronary atherosclerosis: results of the phase 2b, randomized, double‐blind, multicenter, ASSURE Trial</article-title>. <source>Am J Cardiovasc Drugs</source>. <year>2016</year>;<volume>16</volume>:<fpage>55</fpage>–<lpage>65</lpage>.<pub-id pub-id-type="pmid">26385396</pub-id></mixed-citation>
              </ref>
              <ref id="jah32453-bib-0012">
                <label>12</label>
                <mixed-citation publication-type="journal" id="jah32453-cit-0012"><string-name><surname>Stampfer</surname><given-names>MJ</given-names></string-name>, <string-name><surname>Sacks</surname><given-names>FM</given-names></string-name>, <string-name><surname>Salvini</surname><given-names>S</given-names></string-name>, <string-name><surname>Willett</surname><given-names>WC</given-names></string-name>, <string-name><surname>Hennekens</surname><given-names>CH</given-names></string-name>. <article-title>A prospective study of cholesterol, apolipoproteins, and the risk of myocardial infarction</article-title>. <source>N Engl J Med</source>. <year>1991</year>;<volume>325</volume>:<fpage>373</fpage>–<lpage>381</lpage>.<pub-id pub-id-type="pmid">2062328</pub-id></mixed-citation>
              </ref>
              <ref id="jah32453-bib-0013">
                <label>13</label>
                <mixed-citation publication-type="journal" id="jah32453-cit-0013"><collab collab-type="authors">Emerging Risk Factors Collaboration</collab>
, <string-name><surname>Di Angelantonio</surname><given-names>E</given-names></string-name>, <string-name><surname>Gao</surname><given-names>P</given-names></string-name>, <string-name><surname>Pennells</surname><given-names>L</given-names></string-name>, <string-name><surname>Kaptoge</surname><given-names>S</given-names></string-name>, <string-name><surname>Caslake</surname><given-names>M</given-names></string-name>, <string-name><surname>Thompson</surname><given-names>A</given-names></string-name>, <string-name><surname>Butterworth</surname><given-names>AS</given-names></string-name>, <string-name><surname>Sarwar</surname><given-names>N</given-names></string-name>, <string-name><surname>Wormser</surname><given-names>D</given-names></string-name>, <string-name><surname>Saleheen</surname><given-names>D</given-names></string-name>, <string-name><surname>Ballantyne</surname><given-names>CM</given-names></string-name>, <string-name><surname>Psaty</surname><given-names>BM</given-names></string-name>, <string-name><surname>Sundström</surname><given-names>J</given-names></string-name>, <string-name><surname>Ridker</surname><given-names>PM</given-names></string-name>, <string-name><surname>Nagel</surname><given-names>D</given-names></string-name>, <string-name><surname>Gillum</surname><given-names>RF</given-names></string-name>, <string-name><surname>Ford</surname><given-names>I</given-names></string-name>, <string-name><surname>Ducimetiere</surname><given-names>P</given-names></string-name>, <string-name><surname>Kiechl</surname><given-names>S</given-names></string-name>, <string-name><surname>Koenig</surname><given-names>W</given-names></string-name>, <string-name><surname>Dullaart</surname><given-names>RPF</given-names></string-name>, <string-name><surname>Assmann</surname><given-names>G</given-names></string-name>, <string-name><surname>D'Agostino</surname><given-names>RB</given-names></string-name>, <string-name><surname>Dagenais</surname><given-names>GR</given-names></string-name>, <string-name><surname>Cooper</surname><given-names>JA</given-names></string-name>, <string-name><surname>Kromhout</surname><given-names>D</given-names></string-name>, <string-name><surname>Onat</surname><given-names>A</given-names></string-name>, <string-name><surname>Tipping</surname><given-names>RW</given-names></string-name>, <string-name><surname>Gómez‐de‐la‐Cámara</surname><given-names>A</given-names></string-name>, <string-name><surname>Rosengren</surname><given-names>A</given-names></string-name>, <string-name><surname>Sutherland</surname><given-names>SE</given-names></string-name>, <string-name><surname>Gallacher</surname><given-names>J</given-names></string-name>, <string-name><surname>Fowkes</surname><given-names>FGR</given-names></string-name>, <string-name><surname>Casiglia</surname><given-names>E</given-names></string-name>, <string-name><surname>Hofman</surname><given-names>A</given-names></string-name>, <string-name><surname>Salomaa</surname><given-names>V</given-names></string-name>, <string-name><surname>Barrett‐Connor</surname><given-names>E</given-names></string-name>, <string-name><surname>Clarke</surname><given-names>R</given-names></string-name>, <string-name><surname>Brunner</surname><given-names>E</given-names></string-name>, <string-name><surname>Jukema</surname><given-names>JW</given-names></string-name>, <string-name><surname>Simons</surname><given-names>LA</given-names></string-name>, <string-name><surname>Sandhu</surname><given-names>M</given-names></string-name>, <string-name><surname>Wareham</surname><given-names>NJ</given-names></string-name>, <string-name><surname>Khaw</surname><given-names>K‐T</given-names></string-name>, <string-name><surname>Kauhanen</surname><given-names>J</given-names></string-name>, <string-name><surname>Salonen</surname><given-names>JT</given-names></string-name>, <string-name><surname>Howard</surname><given-names>WJ</given-names></string-name>, <string-name><surname>Nordestgaard</surname><given-names>BG</given-names></string-name>, <string-name><surname>Wood</surname><given-names>AM</given-names></string-name>, <string-name><surname>Thompson</surname><given-names>SG</given-names></string-name>, <string-name><surname>Boekholdt</surname><given-names>SM</given-names></string-name>, <string-name><surname>Sattar</surname><given-names>N</given-names></string-name>, <string-name><surname>Packard</surname><given-names>C</given-names></string-name>, <string-name><surname>Gudnason</surname><given-names>V</given-names></string-name>, <string-name><surname>Danesh</surname><given-names>J</given-names></string-name>. <article-title>Lipid‐related markers and cardiovascular disease prediction</article-title>. <source>JAMA</source>. <year>2012</year>;<volume>307</volume>:<fpage>2499</fpage>–<lpage>2506</lpage>.<pub-id pub-id-type="pmid">22797450</pub-id></mixed-citation>
              </ref>
              <ref id="jah32453-bib-0014">
                <label>14</label>
                <mixed-citation publication-type="journal" id="jah32453-cit-0014"><string-name><surname>Day</surname><given-names>N</given-names></string-name>, <string-name><surname>Oakes</surname><given-names>S</given-names></string-name>, <string-name><surname>Luben</surname><given-names>R</given-names></string-name>, <string-name><surname>Khaw</surname><given-names>KT</given-names></string-name>, <string-name><surname>Bingham</surname><given-names>S</given-names></string-name>, <string-name><surname>Welch</surname><given-names>A</given-names></string-name>, <string-name><surname>Wareham</surname><given-names>N</given-names></string-name>. <article-title>EPIC‐Norfolk: study design and characteristics of the cohort. European Prospective Investigation of Cancer</article-title>. <source>Br J Cancer</source>. <year>1999</year>;<volume>80</volume>(<issue>suppl 1</issue>):<fpage>95</fpage>–<lpage>103</lpage>.<pub-id pub-id-type="pmid">10466767</pub-id></mixed-citation>
              </ref>
              <ref id="jah32453-bib-0015">
                <label>15</label>
                <mixed-citation publication-type="journal" id="jah32453-cit-0015"><string-name><surname>Boekholdt</surname><given-names>SM</given-names></string-name>, <string-name><surname>Peters</surname><given-names>RJG</given-names></string-name>, <string-name><surname>Day</surname><given-names>NE</given-names></string-name>, <string-name><surname>Luben</surname><given-names>R</given-names></string-name>, <string-name><surname>Bingham</surname><given-names>SA</given-names></string-name>, <string-name><surname>Wareham</surname><given-names>NJ</given-names></string-name>, <string-name><surname>Hack</surname><given-names>CE</given-names></string-name>, <string-name><surname>Reitsma</surname><given-names>PH</given-names></string-name>, <string-name><surname>Khaw</surname><given-names>K‐T</given-names></string-name>. <article-title>Macrophage migration inhibitory factor and the risk of myocardial infarction or death due to coronary artery disease in adults without prior myocardial infarction or stroke: the EPIC‐Norfolk Prospective Population study</article-title>. <source>Am J Med</source>. <year>2004</year>;<volume>117</volume>:<fpage>390</fpage>–<lpage>397</lpage>.<pub-id pub-id-type="pmid">15380495</pub-id></mixed-citation>
              </ref>
              <ref id="jah32453-bib-0016">
                <label>16</label>
                <mixed-citation publication-type="journal" id="jah32453-cit-0016"><string-name><surname>Friedewald</surname><given-names>WT</given-names></string-name>, <string-name><surname>Levy</surname><given-names>RI</given-names></string-name>, <string-name><surname>Fredrickson</surname><given-names>DS</given-names></string-name>. <article-title>Estimation of the concentration of low‐density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge</article-title>. <source>Clin Chem</source>. <year>1972</year>;<volume>18</volume>:<fpage>499</fpage>–<lpage>502</lpage>.<pub-id pub-id-type="pmid">4337382</pub-id></mixed-citation>
              </ref>
              <ref id="jah32453-bib-0017">
                <label>17</label>
                <mixed-citation publication-type="journal" id="jah32453-cit-0017"><string-name><surname>Albers</surname><given-names>JJ</given-names></string-name>, <string-name><surname>Marcovina</surname><given-names>SM</given-names></string-name>, <string-name><surname>Kennedy</surname><given-names>H</given-names></string-name>. <article-title>International Federation of Clinical Chemistry standardization project for measurements of apolipoproteins A‐I and B. II. Evaluation and selection of candidate reference materials</article-title>. <source>Clin Chem</source>. <year>1992</year>;<volume>38</volume>:<fpage>658</fpage>–<lpage>662</lpage>.<pub-id pub-id-type="pmid">1582016</pub-id></mixed-citation>
              </ref>
              <ref id="jah32453-bib-0018">
                <label>18</label>
                <mixed-citation publication-type="journal" id="jah32453-cit-0018"><article-title>The Atherosclerosis Risk in Communities (ARIC) Study: design and objectives. The ARIC Investigators</article-title>. <source>Am J Epidemiol</source>. <year>1989</year>;<volume>129</volume>:<fpage>687</fpage>–<lpage>702</lpage>.<pub-id pub-id-type="pmid">2646917</pub-id></mixed-citation>
              </ref>
              <ref id="jah32453-bib-0019">
                <label>19</label>
                <mixed-citation publication-type="journal" id="jah32453-cit-0019"><string-name><surname>White</surname><given-names>AD</given-names></string-name>, <string-name><surname>Folsom</surname><given-names>AR</given-names></string-name>, <string-name><surname>Chambless</surname><given-names>LE</given-names></string-name>, <string-name><surname>Sharret</surname><given-names>AR</given-names></string-name>, <string-name><surname>Yang</surname><given-names>K</given-names></string-name>, <string-name><surname>Conwill</surname><given-names>D</given-names></string-name>, <string-name><surname>Higgins</surname><given-names>M</given-names></string-name>, <string-name><surname>Williams</surname><given-names>OD</given-names></string-name>, <string-name><surname>Tyroler</surname><given-names>HA</given-names></string-name>. <article-title>Community surveillance of coronary heart disease in the Atherosclerosis Risk in Communities (ARIC) Study: methods and initial two years’ experience</article-title>. <source>J Clin Epidemiol</source>. <year>1996</year>;<volume>49</volume>:<fpage>223</fpage>–<lpage>233</lpage>.<pub-id pub-id-type="pmid">8606324</pub-id></mixed-citation>
              </ref>
              <ref id="jah32453-bib-0020">
                <label>20</label>
                <mixed-citation publication-type="journal" id="jah32453-cit-0020"><string-name><surname>Sharrett</surname><given-names>AR</given-names></string-name>, <string-name><surname>Patsch</surname><given-names>W</given-names></string-name>, <string-name><surname>Sorlie</surname><given-names>PD</given-names></string-name>, <string-name><surname>Heiss</surname><given-names>G</given-names></string-name>, <string-name><surname>Bond</surname><given-names>MG</given-names></string-name>, <string-name><surname>Davis</surname><given-names>CE</given-names></string-name>. <article-title>Associations of lipoprotein cholesterols, apolipoproteins A‐I and B, and triglycerides with carotid atherosclerosis and coronary heart disease. The Atherosclerosis Risk in Communities (ARIC) Study</article-title>. <source>Arterioscler Thromb Vasc Biol</source>. <year>1994</year>;<volume>14</volume>:<fpage>1098</fpage>–<lpage>1104</lpage>.</mixed-citation>
              </ref>
              <ref id="jah32453-bib-0021">
                <label>21</label>
                <mixed-citation publication-type="journal" id="jah32453-cit-0021"><string-name><surname>Ridker</surname><given-names>PM</given-names></string-name>, <string-name><surname>Cook</surname><given-names>NR</given-names></string-name>, <string-name><surname>Lee</surname><given-names>I‐M</given-names></string-name>, <string-name><surname>Gordon</surname><given-names>D</given-names></string-name>, <string-name><surname>Gaziano</surname><given-names>JM</given-names></string-name>, <string-name><surname>Manson</surname><given-names>JE</given-names></string-name>, <string-name><surname>Hennekens</surname><given-names>CH</given-names></string-name>, <string-name><surname>Buring</surname><given-names>JE</given-names></string-name>. <article-title>A randomized trial of low‐dose aspirin in the primary prevention of cardiovascular disease in women</article-title>. <source>N Engl J Med</source>. <year>2005</year>;<volume>352</volume>:<fpage>1293</fpage>–<lpage>1304</lpage>.<pub-id pub-id-type="pmid">15753114</pub-id></mixed-citation>
              </ref>
              <ref id="jah32453-bib-0022">
                <label>22</label>
                <mixed-citation publication-type="journal" id="jah32453-cit-0022"><string-name><surname>Mora</surname><given-names>S</given-names></string-name>, <string-name><surname>Buring</surname><given-names>JE</given-names></string-name>, <string-name><surname>Ridker</surname><given-names>PM</given-names></string-name>, <string-name><surname>Cui</surname><given-names>Y</given-names></string-name>. <article-title>Association of high‐density lipoprotein cholesterol with incident cardiovascular events in women, by low‐density lipoprotein cholesterol and apolipoprotein B100 levels: a cohort study</article-title>. <source>Ann Intern Med</source>. <year>2011</year>;<volume>155</volume>:<fpage>742</fpage>–<lpage>750</lpage>.<pub-id pub-id-type="pmid">22147713</pub-id></mixed-citation>
              </ref>
              <ref id="jah32453-bib-0023">
                <label>23</label>
                <mixed-citation publication-type="journal" id="jah32453-cit-0023"><string-name><surname>Grundy</surname><given-names>SM</given-names></string-name>. <article-title>Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines</article-title>. <source>Arterioscler Thromb Vasc Biol</source>. <year>2004</year>;<volume>24</volume>:<fpage>e149</fpage>–<lpage>e161</lpage>.<pub-id pub-id-type="pmid">15297292</pub-id></mixed-citation>
              </ref>
              <ref id="jah32453-bib-0024">
                <label>24</label>
                <mixed-citation publication-type="journal" id="jah32453-cit-0024"><string-name><surname>McQueen</surname><given-names>MJ</given-names></string-name>, <string-name><surname>Hawken</surname><given-names>S</given-names></string-name>, <string-name><surname>Wang</surname><given-names>X</given-names></string-name>, <string-name><surname>Ounpuu</surname><given-names>S</given-names></string-name>, <string-name><surname>Sniderman</surname><given-names>A</given-names></string-name>, <string-name><surname>Probstfield</surname><given-names>J</given-names></string-name>, <string-name><surname>Steyn</surname><given-names>K</given-names></string-name>, <string-name><surname>Sanderson</surname><given-names>JE</given-names></string-name>, <string-name><surname>Hasani</surname><given-names>M</given-names></string-name>, <string-name><surname>Volkova</surname><given-names>E</given-names></string-name>, <string-name><surname>Kazmi</surname><given-names>K</given-names></string-name>, <string-name><surname>Yusuf</surname><given-names>S</given-names></string-name>; <collab collab-type="authors">INTERHEART study investigators</collab>
. <article-title>Lipids, lipoproteins, and apolipoproteins as risk markers of myocardial infarction in 52 countries (the INTERHEART study): a case‐control study</article-title>. <source>Lancet</source>. <year>2008</year>;<volume>372</volume>:<fpage>224</fpage>–<lpage>233</lpage>.<pub-id pub-id-type="pmid">18640459</pub-id></mixed-citation>
              </ref>
              <ref id="jah32453-bib-0025">
                <label>25</label>
                <mixed-citation publication-type="journal" id="jah32453-cit-0025"><string-name><surname>van der Steeg</surname><given-names>WA</given-names></string-name>, <string-name><surname>Holme</surname><given-names>I</given-names></string-name>, <string-name><surname>Boekholdt</surname><given-names>SM</given-names></string-name>, <string-name><surname>Larsen</surname><given-names>ML</given-names></string-name>, <string-name><surname>Lindahl</surname><given-names>C</given-names></string-name>, <string-name><surname>Stroes</surname><given-names>ESG</given-names></string-name>, <string-name><surname>Tikkanen</surname><given-names>MJ</given-names></string-name>, <string-name><surname>Wareham</surname><given-names>NJ</given-names></string-name>, <string-name><surname>Faergeman</surname><given-names>O</given-names></string-name>, <string-name><surname>Olsson</surname><given-names>AG</given-names></string-name>, <string-name><surname>Pedersen</surname><given-names>TR</given-names></string-name>, <string-name><surname>Khaw</surname><given-names>K‐T</given-names></string-name>, <string-name><surname>Kastelein</surname><given-names>JJP</given-names></string-name>. <article-title>High‐density lipoprotein cholesterol, high‐density lipoprotein particle size, and apolipoprotein A‐I: significance for cardiovascular risk</article-title>. <source>J Am Coll Cardiol</source>. <year>2008</year>;<volume>51</volume>:<fpage>634</fpage>–<lpage>642</lpage>.<pub-id pub-id-type="pmid">18261682</pub-id></mixed-citation>
              </ref>
              <ref id="jah32453-bib-0026">
                <label>26</label>
                <mixed-citation publication-type="journal" id="jah32453-cit-0026"><string-name><surname>Walker</surname><given-names>BR</given-names></string-name>. <article-title>Abnormal glucocorticoid activity in subjects with risk factors for cardiovascular disease</article-title>. <source>Endocr Res</source>. <year>1996</year>;<volume>22</volume>:<fpage>701</fpage>–<lpage>708</lpage>.<pub-id pub-id-type="pmid">8969930</pub-id></mixed-citation>
              </ref>
              <ref id="jah32453-bib-0027">
                <label>27</label>
                <mixed-citation publication-type="journal" id="jah32453-cit-0027"><string-name><surname>Berg</surname><given-names>AL</given-names></string-name>, <string-name><surname>Nilsson‐Ehle</surname><given-names>P</given-names></string-name>. <article-title>Direct effects of corticotropin on plasma lipoprotein metabolism in man—studies in vivo and in vitro</article-title>. <source>Metabolism</source>. <year>1994</year>;<volume>43</volume>:<fpage>90</fpage>–<lpage>97</lpage>.<pub-id pub-id-type="pmid">8289680</pub-id></mixed-citation>
              </ref>
              <ref id="jah32453-bib-0028">
                <label>28</label>
                <mixed-citation publication-type="journal" id="jah32453-cit-0028"><string-name><surname>Dunaif</surname><given-names>A</given-names></string-name>. <article-title>Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis</article-title>. <source>Endocr Rev</source>. <year>1997</year>;<volume>18</volume>:<fpage>774</fpage>–<lpage>800</lpage>.<pub-id pub-id-type="pmid">9408743</pub-id></mixed-citation>
              </ref>
              <ref id="jah32453-bib-0029">
                <label>29</label>
                <mixed-citation publication-type="journal" id="jah32453-cit-0029"><string-name><surname>Wang</surname><given-names>CN</given-names></string-name>, <string-name><surname>McLeod</surname><given-names>RS</given-names></string-name>, <string-name><surname>Yao</surname><given-names>Z</given-names></string-name>, <string-name><surname>Brindley</surname><given-names>DN</given-names></string-name>. <article-title>Effects of dexamethasone on the synthesis, degradation, and secretion of apolipoprotein B in cultured rat hepatocytes</article-title>. <source>Arterioscler Thromb Vasc Biol</source>. <year>1995</year>;<volume>15</volume>:<fpage>1481</fpage>–<lpage>1491</lpage>.<pub-id pub-id-type="pmid">7670964</pub-id></mixed-citation>
              </ref>
              <ref id="jah32453-bib-0030">
                <label>30</label>
                <mixed-citation publication-type="journal" id="jah32453-cit-0030"><string-name><surname>Rosenson</surname><given-names>RS</given-names></string-name>, <string-name><surname>Brewer</surname><given-names>HB</given-names></string-name>, <string-name><surname>Chapman</surname><given-names>MJ</given-names></string-name>, <string-name><surname>Fazio</surname><given-names>S</given-names></string-name>, <string-name><surname>Hussain</surname><given-names>MM</given-names></string-name>, <string-name><surname>Kontush</surname><given-names>A</given-names></string-name>, <string-name><surname>Krauss</surname><given-names>RM</given-names></string-name>, <string-name><surname>Otvos</surname><given-names>JD</given-names></string-name>, <string-name><surname>Remaley</surname><given-names>AT</given-names></string-name>, <string-name><surname>Schaefer</surname><given-names>EJ</given-names></string-name>. <article-title>HDL measures, particle heterogeneity, proposed nomenclature, and relation to atherosclerotic cardiovascular events</article-title>. <source>Clin Chem</source>. <year>2011</year>;<volume>57</volume>:<fpage>392</fpage>–<lpage>410</lpage>.<pub-id pub-id-type="pmid">21266551</pub-id></mixed-citation>
              </ref>
            </ref-list>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
